

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 13, 2003, 15:31:05 ; Search time 10.4014 Seconds

(without alignments)
596.865 Million cell updates/sec

Title: US-09-728-911-34

Perfect score: 1142

Sequence: 1 PEDPSDLQHVKFGSSNFEN.....AKESAPYMCVKTLTPDRTWT 211

Scoring table:

Gapop 10.0, Gapext 0.5

Searched: 262574 seqs, 29422922 residues

Number of hits satisfying chosen parameters: 262574

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: Issued Patents AA:*

- 1: /cgn2_6/prodata/1/1aa/5A.COMB.pep:*
- 2: /cgn2_6/prodata/1/1aa/5B.COMB.pep:*
- 3: /cgn2_6/prodata/1/1aa/6A.COMB.pep:*
- 4: /cgn2_6/prodata/1/1aa/6B.COMB.pep:*
- 5: /cgn2_6/prodata/1/1aa/PCTUS.COMB.pep:*
- 6: /cgn2_6/prodata/1/1aa/backfile1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1142	100.0	574	2	US-08-906-713-2
2	194.5	17.0	221	2	US-08-943-087-58
3	192.5	16.9	221	2	US-08-943-087-56
4	191.5	16.8	221	2	US-08-943-087-50
5	191.5	16.8	553	2	US-08-943-087-2
6	191.5	16.8	553	2	US-08-943-087-14
7	191.5	16.8	553	2	US-08-943-087-16
8	191.5	16.8	553	2	US-08-943-087-18
9	191.5	16.8	553	2	US-08-943-087-20
10	191.5	16.8	553	2	US-08-943-087-22
11	191.5	16.8	553	2	US-08-943-087-24
12	191.5	16.8	553	2	US-08-943-087-26
13	191.5	16.8	553	2	US-08-943-087-28
14	191.5	16.8	553	2	US-08-943-087-30
15	191.5	16.8	553	2	US-08-943-087-32
16	191.5	16.8	553	2	US-08-943-087-34
17	191.5	16.8	553	2	US-08-943-087-36
18	191.5	16.8	553	2	US-08-943-087-38
19	191.5	16.8	553	2	US-08-943-087-40
20	191.5	16.8	553	2	US-08-943-087-42
21	191.5	16.8	553	2	US-08-943-087-44
22	191.5	16.8	553	2	US-08-943-087-46
23	191.5	16.8	553	2	US-08-943-087-48
24	189.5	16.6	221	2	US-08-943-087-52
25	189.5	16.6	221	2	US-08-943-087-54
26	189.5	16.6	221	2	US-08-943-087-60
27	143	12.5	559	1	US-08-424-788-3

28	143	12.5	575	1	US-08-424-788-2	Sequence 2, Appl1
29	143	12.5	575	1	US-08-110-683-4	Sequence 4, Appl1
30	143	12.5	575	2	US-08-477-166-4	Sequence 4, Appl1
31	143	12.5	575	2	US-08-472-166-4	Sequence 4, Appl1
32	143	12.5	575	2	US-09-459-672-4	Sequence 4, Appl1
33	143	12.5	575	4	PCT-US93-11638-4	Sequence 4, Appl1
34	131.5	11.5	224	4	US-08-871-572B-9	Sequence 9, Appl1
35	131.5	11.5	434	1	US-08-328-256-11	Sequence 11, Appl1
36	131.5	11.5	436	2	US-08-307-588-4	Sequence 12, Appl1
37	131.5	11.5	496	1	US-08-328-256-12	Sequence 10, Appl1
38	131.5	11.5	557	1	US-08-328-256-10	Sequence 2, Appl1
39	131.5	11.5	557	2	US-08-471-454-2	Sequence 2, Appl1
40	131.5	11.5	557	2	US-08-466-974-2	Sequence 2, Appl1
41	131.5	11.5	557	2	US-08-471-453-2	Sequence 2, Appl1
42	131.5	11.5	557	2	US-08-307-588-4	Sequence 4, Appl1
43	128.5	11.3	224	4	US-08-871-572B-13	Sequence 13, Appl1
44	118	10.3	218	1	US-07-816-677A-3	Sequence 3, Appl1
45	118	10.3	218	5	PCT-US92-11270-3	Sequence 3, Appl1

ALIGNMENTS

RESULT 1

US-08-906-713-2

Sequence 2, Application US/08906713

Patent No. 5965704

GENERAL INFORMATION:

APPLICANT: Lok, Si

APPLICANT: Adams, Robyn L.

APPLICANT: Jeimberg, Anna C.

APPLICANT: Whitmore, Theodore E.

TITLE OF INVENTION: MAMMALIAN ZCYTOR11

NUMBER OF SEQUENCES: 6

CORRESPONDENCE ADDRESS:

ADDRESSER: Zymogenetics

STREET: 1201 Eastlake Ave East

CITY: Seattle

STATE: WA

COUNTRY: USA

ZIP: 98102

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS

SOFTWARE: FASTSEQ for Windows Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: 536

FILING DATE: 08/06/713

CLASSIFICATION: 536

PRIOR APPLICATION DATA:

APPLICATION NUMBER:

FILING DATE:

ATTORNEY/AGENT INFORMATION:

NAME: Lunn, Paul G

REGISTRATION NUMBER: 32,743

REFERENCE/DOCKET NUMBER: 97-52

TELECOMMUNICATION INFORMATION:

TELEPHONE: 206-442-6677

TELEFAX: 206-442-6678

TELEX:

INFORMATION FOR SEQ ID NO: 2:

SEQUENCE CHARACTERISTICS:

LENGTH: 574 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: protein

FRAGMENT TYPE: internal

US-08-906-713-2

Query Match

100.0%; Score 1142; DB 2; Length 574;

us-09-728-911-34.ra1

Mon Jan 13 15:37:35 2003

Best Local Similarity 100.0%; Pred. No. 5.1e-131; Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PEDPSDLLQHVKFOSSNFENILTWDSGPEGTPTDVTYVSIYKTYGERDVAKKGCQRITRK 60
 Db 18 PEDPSDLLQHVKFOSSNFENILTWDSGPEGTPTDVTYVSIYKTYGERDVAKKGCQRITRK 77
 QY 61 SGNLTVEGNLTLYYARVTAVSAGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIOM 120
 Db 78 SGNLTVEGNLTLYYARVTAVSAGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIOM 137
 QY 121 IVHPTPTPIRAGDGHRLTLEDFHDLFYHLEQVNRITVQMHGKGKQREYEFFGLTPDTEF 180
 Db 138 IVHPTPTPIRAGDGHRLTLEDFHDLFYHLEQVNRITVQMHGKGKQREYEFFGLTPDTEF 197
 QY 181 LGTICVPTWAKESAPYMCVRKTLPPDRITWT 211
 Db 198 LGTICVPTWAKESAPYMCVRKTLPPDRITWT 228

RESULT 2
 US-08-943-087-58
 ; Sequence 58, Application US/08943087
 ; Patent No. 5945511
 ; GENERAL INFORMATION:
 ; APPLICANT: Lok, Si
 ; APPLICANT: Kho, Choon J.
 ; APPLICANT: Jelmsberg, Anna C.
 ; APPLICANT: Adams, Robyn L.
 ; APPLICANT: Whitmore, Theodore E.
 ; APPLICANT: Farrah, Theresa M.
 ; TITLE OF INVENTION: CYTOKINE RECEPTOR
 ; NUMBER OF SEQUENCES: 60
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: ZymoGenetics, Inc.
 ; STREET: 1201 Eastlake Avenue East
 ; CITY: Seattle
 ; STATE: WA
 ; COUNTRY: USA
 ; ZIP: 98102
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Diskette
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: DOS
 ; SOFTWARE: FastSEQ for Windows Version 2.0
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/943,087
 ; FILING DATE:
 ; CLASSIFICATION: 536
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 08/803,305
 ; FILING DATE: 20-FEB-1997
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Lunn, Paul G
 ; REGISTRATION NUMBER: 32,743
 ; REFERENCE/DOCKET NUMBER: 96-24C1
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 206-442-6627
 ; TELEFAX: 206-442-6678
 ; TELEX:
 ; INFORMATION FOR SEQ ID NO: 58:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 221 amino acids
 ; TYPE: amino acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: protein
 ; FRAGMENT TYPE: internal
 ; US-08-943-087-58

Query Match 17.0%; Score 194.5; DB 2; Length 221;
 Best Local Similarity 26.8%; Pred. No. 1.4e-15;
 Matches 56; Conservative 44; Mismatches 94; Indels 15; Gaps 8;

QY 10 HVAFQSSNFENILTWDSGPEGTPTDVTYVSIYKTYGERDVAKKGCQRITRKSCNLTVE 67
 Db 13 NIIFLSINMKNVLQW--TPPEGLQGVKVTYVQYFIYQKKLWNSDCRNINNTYCDLSAD 71
 QY 68 TGNLTLYYARVTAVSAGRSATKMTD--RFSSLQHTTLKPPDVTCISKVRSIOMIVHPT 125
 Db 72 TSDYDHOYAKVXAI--WGTCKSKWADSGRFYFPLDTQIGPPEVALTTDEKSISSVLTAP 129
 QY 126 PTPIRAGDGHRLTLEDFHDLFYH---LEQVNRITVQMHGKGKQREYEFFGLTPDTEFLG 182
 Db 130 EKWRNPDPLVSNQYIYNLKNVSVLNTKSNRTWSQCV--TNHTLVLTWLEPNTLYCV 187
 QY 183 TIMICVPTWAKESAP--YMCVRKTLPPDRITWT 209
 Db 188 HVESFVPGPPRRAPQSEKQC-ARTLKDQS 215

RESULT 3
 US-08-943-087-56
 ; Sequence 56, Application US/08943087
 ; Patent No. 5945511
 ; GENERAL INFORMATION:
 ; APPLICANT: Lok, Si
 ; APPLICANT: Kho, Choon J.
 ; APPLICANT: Jelmsberg, Anna C.
 ; APPLICANT: Adams, Robyn L.
 ; APPLICANT: Whitmore, Theodore E.
 ; APPLICANT: Farrah, Theresa M.
 ; TITLE OF INVENTION: CYTOKINE RECEPTOR
 ; NUMBER OF SEQUENCES: 60
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: ZymoGenetics, Inc.
 ; STREET: 1201 Eastlake Avenue East
 ; CITY: Seattle
 ; STATE: WA
 ; COUNTRY: USA
 ; ZIP: 98102
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Diskette
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: DOS
 ; SOFTWARE: FastSEQ for Windows Version 2.0
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/943,087
 ; FILING DATE:
 ; CLASSIFICATION: 536
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 08/803,305
 ; FILING DATE: 20-FEB-1997
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Lunn, Paul G
 ; REGISTRATION NUMBER: 32,743
 ; REFERENCE/DOCKET NUMBER: 96-24C1
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 206-442-6627
 ; TELEFAX: 206-442-6678
 ; TELEX:
 ; INFORMATION FOR SEQ ID NO: 56:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 221 amino acids
 ; TYPE: amino acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: protein
 ; FRAGMENT TYPE: internal
 ; US-08-943-087-56

Query Match 16.9%; Score 192.5; DB 2; Length 221;
 Best Local Similarity 25.6%; Pred. No. 2.5e-15;
 Matches 55; Conservative 44; Mismatches 89; Indels 27; Gaps 8;

QY 10 HVKVFQSSNFENILTWDSGPEGTPTDVTYVSIYKTYGERDVAKKGCQRITRKSCNLTVE 67

GenCore version 5.1.3
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 13, 2003, 15:28:46 ; Search time 29.223 Seconds
(without alignments)
962.115 Million cell updates/sec

Title: US-09-728-911-34

Perfect score: 1142

Sequence: 1 PEDPSDLQHVXKFOSSNFEN.....AKSAPYMKCVKTLPTDRTWT 211

Scoring table:

BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_101002:*

- 1: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1980.DAT:*
- 2: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1981.DAT:*
- 3: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1982.DAT:*
- 4: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1983.DAT:*
- 5: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1984.DAT:*
- 6: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1985.DAT:*
- 7: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1986.DAT:*
- 8: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1987.DAT:*
- 9: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1988.DAT:*
- 10: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1989.DAT:*
- 11: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1990.DAT:*
- 12: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1991.DAT:*
- 13: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1992.DAT:*
- 14: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1993.DAT:*
- 15: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1994.DAT:*
- 16: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1995.DAT:*
- 17: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1996.DAT:*
- 18: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1997.DAT:*
- 19: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:*
- 20: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1999.DAT:*
- 21: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA2000.DAT:*
- 22: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA2001.DAT:*
- 23: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1142	100.0	211	20	AAW97864 Human cytokine rec
2	1142	100.0	211	20	AAW97864 Human cytokine rec
3	1142	100.0	211	23	AAU76906 Human Z-cytoII s
4	1142	100.0	484	23	AAU76916 Human ZcytoII/1g6
5	1142	100.0	574	20	AAW97861 Human cytokine rec
6	1142	100.0	574	21	AAW97861 Human cytokine rec
7	1142	100.0	574	22	AAW97861 Human cytokine rec
8	1142	100.0	574	22	AAW97861 Human cytokine rec
9	1142	100.0	574	22	AAW97861 Human cytokine rec
10	1142	100.0	574	23	AAU76905 Human Z-cytoII p

11	1142	100.0	574	23	AAU78083 Human interleukin
12	854	74.8	196	22	AAW24345 Human EST encoded
13	691	60.5	353	21	AAW97047 Partial murine TAN
14	263	23.0	210	22	AAW62663 Human ZcytoII ext
15	263	23.0	214	23	AAE17319 Human cytokine rec
16	263	23.0	231	22	AAE05048 Human ZCYTO18 soln
17	263	23.0	231	22	AAE02460 Human cytokine rec
18	263	23.0	231	22	AAE02460 Human cytokine rec
19	263	23.0	231	23	AAW62657 Human cytokine rec
20	263	23.0	231	23	AAW62657 Human cytokine rec
21	263	23.0	231	23	AAW62657 Human cytokine rec
22	263	23.0	231	23	AAW62657 Human cytokine rec
23	263	23.0	231	23	AAW62657 Human cytokine rec
24	263	23.0	231	23	AAW62657 Human cytokine rec
25	263	23.0	231	23	AAW62657 Human cytokine rec
26	263	23.0	231	23	AAW62657 Human cytokine rec
27	263	23.0	231	23	AAW62657 Human cytokine rec
28	263	23.0	231	23	AAW62657 Human cytokine rec
29	263	23.0	231	23	AAW62657 Human cytokine rec
30	263	23.0	231	23	AAW62657 Human cytokine rec
31	263	23.0	231	23	AAW62657 Human cytokine rec
32	263	23.0	231	23	AAW62657 Human cytokine rec
33	263	23.0	231	23	AAW62657 Human cytokine rec
34	263	23.0	231	23	AAW62657 Human cytokine rec
35	263	23.0	231	23	AAW62657 Human cytokine rec
36	263	23.0	231	23	AAW62657 Human cytokine rec
37	263	23.0	231	23	AAW62657 Human cytokine rec
38	263	23.0	231	23	AAW62657 Human cytokine rec
39	263	23.0	231	23	AAW62657 Human cytokine rec
40	263	23.0	231	23	AAW62657 Human cytokine rec
41	263	23.0	231	23	AAW62657 Human cytokine rec
42	263	23.0	231	23	AAW62657 Human cytokine rec
43	263	23.0	231	23	AAW62657 Human cytokine rec
44	263	23.0	231	23	AAW62657 Human cytokine rec
45	263	23.0	231	23	AAW62657 Human cytokine rec

ALIGNMENTS

RESULT 1
ID AAW97864 standard; Protein; 211 AA.
AAW97864;
AC AAW97864;
XX 07-JUN-1999 (first entry)
DT Human cytokine receptor 11 (ZcytoII) extracellular domain.
XX Human cytokine receptor 11; ZcytoII; human; pancreas; small intestine;
XX Cytokine receptor 11; ZcytoII; human; pancreas; small intestine;
XX colon; thymus.
XX Homo sapiens.
XX WO9907848-A1.
XX 18-FEB-1999.
XX 30-JUN-1998; 98WO-US15847.
XX 05-AUG-1997; 97US-0906713.
XX (ZYMO) ZYMOGENETICS INC.
XX Adams RL, Farrah TM, Jellumberg AC, Lok S, Whitmore TE;
XX WPI; 1999-167425/14.
XX Novel human cytokine receptor ZcytoII - useful for screening for
XX ligands to modulate or promote proliferation and/or differentiation
XX of e.g. pancreatic or colon tissue

PS Claim 20; Page 58-59; 62pp; English.

XX This polypeptide comprises the extracellular domain (residues
CC 18-228) of human cytokine receptor 11 (Zcytor11), a novel class II
CC cytokine receptor that appears to be a receptor for a helical
CC cytokine of the interferon/interleukin-10 class. Zcytor11 (see
CC also AAW97861) is a cell surface receptor that is expressed in
CC pancreas, small intestine, colon and thymus. Novel Zcytor11
CC polypeptides, including the extracellular domain, can be used to
CC detect ligands that promote the proliferation and/or differentiation
CC of these organs. The invention provides claimed expression vectors
CC and transformed or transfected cells, as well as an antibody that
CC specifically binds to the extracellular domain of Zcytor11, and an
CC anti-idiotypic antibody. The vectors include a promoter, a
CC terminator and DNA encoding the extracellular domain, signal
CC sequence, transmembrane domain (see AAW97865) or intracellular domain
CC (see AAW97866) of Zcytor11.

SQ Sequence 211 AA;

Query Match 100.0%; Score 1142; DB 20; Length 211;
Best Local Similarity 100.0%; Pred. No. 3.3e-121;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PEDPSDLLQHVQFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDVAKKGQRIIRK 60
DB 1 PEDPSDLLQHVQFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDVAKKGQRIIRK 60
QY 61 SCNLTVETGNLTLYYARVAVSAGRSATKMTDRFSSLQHTTLKPPDVTICISKVRSIQ 120
DB 61 SCNLTVETGNLTLYYARVAVSAGRSATKMTDRFSSLQHTTLKPPDVTICISKVRSIQ 120
QY 121 IVHPTPTPIRAGDGHRLTLEDIFHDLFVHLELVNRTYQMHGKQREYFFGLTPDTEF 180
DB 121 IVHPTPTPIRAGDGHRLTLEDIFHDLFVHLELVNRTYQMHGKQREYFFGLTPDTEF 180
QY 181 LGTIMICVPTWAKESAPYMCVRKTLPTDRTWT 211
DB 181 LGTIMICVPTWAKESAPYMCVRKTLPTDRTWT 211

RESULT 2

AA62666
ID AAB62666 standard; Protein; 211 AA.

XX AC AAB62666;

DE 23-JUL-2001 (first entry)

XX Human zcytor11 receptor fragment.

XX Cytokine receptor; zcytor16; IL-TIF; antiinflammatory; cytostatic;
KW antiarthritis; antiarthritic; antiasthmatic; antiatherosclerotic;
KW immunosuppressive; chromosome 6q24.1-25.2; human; zcytor11.

XX Homo sapiens.

XX WO200140467-A1.

XX 07-JUN-2001.

XX 01-DEC-2000; 2000WO-US322703.

XX 03-DEC-1999; 99US-0169049.

XX 13-SEP-2000; 2000US-0232219.

XX 31-OCT-2000; 2000US-0244610.

XX (ZYMO) ZYMOGENETICS INC.

XX Presnell SR, Xu W, Kindsvogel W, Chen Z;

XX WPI; 2001-356158/37.

PT New soluble cytokine receptor polypeptides and polynucleotides, useful
PT for diagnosing and treating cancer and inflammatory conditions -
XX Claim 46; Page 206-207; 210pp; English.

XX The invention relates to a human cytokine receptor polypeptide,
CC designated zcytor16. The zcytor16 polypeptide can be expressed by
CC standard recombinant methodology and can bind to IL-TIF (undefined). The
CC zcytor16 protein is useful for: inhibiting IL-TIF induced proliferation
CC or differentiation of hematopoietic cell(s) (progenitors); reducing
CC IL-TIF induced or IL-9 induced inflammation; and suppressing an
CC inflammatory response in a mammal with inflammation. Heteromeric/
CC multimeric receptor polypeptides such as soluble zcytor 16/CRP2-4 can be
CC used to reduce progression and symptoms of cancer. Zcytor16 polypeptides
CC can also be used to detect IL-TIF levels which is indicative of
CC pathological conditions including inflammatory states (e.g. rheumatoid
CC arthritis) and cancer. Antibodies that bind zcytor16 polypeptides and the
CC polypeptides themselves are useful for the treatment of inflammation,
CC inflammatory diseases (e.g. infection, asthma, inflammatory bowel
CC disease, rheumatoid arthritis and atherosclerosis) and autoimmune
CC diseases. The antibodies and zcytor16 polynucleotides are also useful
CC for detecting cancer. The present sequence represents the human zcytor11
CC receptor protein fragment which forms a receptor complex with zcytor16.

SQ Sequence 211 AA;

Query Match 100.0%; Score 1142; DB 22; Length 211;
Best Local Similarity 100.0%; Pred. No. 3.3e-121;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PEDPSDLLQHVQFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDVAKKGQRIIRK 60
DB 1 PEDPSDLLQHVQFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDVAKKGQRIIRK 60
QY 61 SCNLTVETGNLTLYYARVAVSAGRSATKMTDRFSSLQHTTLKPPDVTICISKVRSIQ 120
DB 61 SCNLTVETGNLTLYYARVAVSAGRSATKMTDRFSSLQHTTLKPPDVTICISKVRSIQ 120
QY 121 IVHPTPTPIRAGDGHRLTLEDIFHDLFVHLELVNRTYQMHGKQREYFFGLTPDTEF 180
DB 121 IVHPTPTPIRAGDGHRLTLEDIFHDLFVHLELVNRTYQMHGKQREYFFGLTPDTEF 180
QY 181 LGTIMICVPTWAKESAPYMCVRKTLPTDRTWT 211
DB 181 LGTIMICVPTWAKESAPYMCVRKTLPTDRTWT 211

RESULT 3

AAU76906

ID AAU76906 standard; Protein; 211 AA.

XX AC AAU76906;

XX 05-JUN-2002 (first entry)

XX Human Z-cytot-II soluble extracellular domain protein.

XX Z-Cytot II; human; cytokine receptor; atopy; psoriasis;
KW interleukin-T-cell inducible factor; IL-TIF; allergy; asthma;
KW receptor-modulated apoptosis; Th1; immune response; pancreatitis;
KW type I diabetes; IDDM; pancreatic cancer; Graves disease; SLE;
KW inflammatory bowel disease; IBD; Crohn's disease; colon cancer;
KW intestinal cancer; diverticulosis; autoimmune disease; sepsis;
KW multiple sclerosis; MS; systemic lupus erythematosus;
KW myasthenia gravis; rheumatoid arthritis; kidney dysfunction.

OS Homo sapiens.

XX WO200212345-A2.

XX 14-FEB-2002.

XX 08-AUG-2001; 2001WO-US24838.

XX 08-AUG-2000; 2000US-223827P.
 PR 01-DEC-2000; 2000US-250876P.
 XX (ZYMO) ZYMOGENETICS INC.
 PA Kindvogel WR, Topouzis S;
 PI Kindvogel WR, Topouzis S;
 DR WPI: 2002-217182/27.
 DR N-PSDB; ABK10501.
 XX New soluble cytokine receptor which binds interleukin-T-cell inducible
 PT factor and antagonizes its activity in inflammatory and immune diseases
 PT such as cancer, diabetes, asthma, sepsis, psoriasis and autoimmune
 PT diseases
 XX
 PS Claim 31; Page 94-95; 117pp; English.
 CC This invention relates to the protein and cDNA sequences of a novel
 CC soluble cytokine receptor polypeptide designated zcytoril, which binds
 CC interleukin-T-cell inducible factor (IL-TIF) or antagonizes IL-TIF
 CC activity. The protein of the invention is useful for reducing IL-TIF-
 CC or IL-9 induced inflammation, and inhibiting IL-TIF-induced
 CC proliferation. The protein is also useful for suppressing an immune
 CC response in a mammal exposed to an antigen or pathogen. Soluble zcytoril
 CC receptor or heterodimeric polypeptide is useful for enhancing the in
 CC vivo killing of target tissues by directly stimulating a zcytoril
 CC receptor-modulated apoptotic pathway. IL-TIF is involved in promoting
 CC Th1-type immune responses and antagonists of IL-TIF have beneficial use
 CC against diseases involving such immune responses. Soluble zcytoril
 CC heterodimers are useful as antagonists in inflammatory and immune
 CC diseases or conditions such as pancreatitis, type I diabetes (IDDM),
 CC pancreatic cancer, Graves disease, inflammatory bowel disease (IBD),
 CC Crohn's disease, colon and intestinal cancer, diverticulosis, autoimmune
 CC disease (e.g. IDDM, multiple sclerosis (MS), systemic lupus
 CC erythematosus (SLE), myasthenia gravis, rheumatoid arthritis and IBD),
 CC sepsis, asthma, allergy and other atopic diseases, psoriasis and kidney
 CC dysfunction. Soluble zcytoril receptor or heterodimeric receptor
 CC polypeptides are useful in vivo or in diagnostic applications to detect
 CC IL-TIF expressing cancers in vivo or in tissue samples and to prepare
 CC an antagonizing Mab inhibits cancer growth and targets immune-mediated
 CC killing. The present sequence represents the soluble extracellular
 CC domain of the zcytoril protein of the invention
 CC
 XX Sequence 211 AA;
 SQ
 Query Match 100.0%; Score 1142; DB 23; Length 211;
 Best Local Similarity 100.0%; Pred. No. 3.3e-121;
 Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PEDSLLQHVKQSSNFENILTWDSGEGTPTTVSIEKTYGGEWDWAKKCCQRIIRK 60
 Db 1 PEDSLLQHVKQSSNFENILTWDSGEGTPTTVSIEKTYGGEWDWAKKCCQRIIRK 60
 QY 61 SCULVETGMLTLYARVAVSAGRSATKMTDRFSSLOHTTLKPPDVTCSKRSIOM 120
 Db 61 SCULVETGMLTLYARVAVSAGRSATKMTDRFSSLOHTTLKPPDVTCSKRSIOM 120
 QY 121 IVHPTPIRAGDGRHLLTLEDFHDLFYHLEQVNTYOMHGGQREYFGLTPDET 180
 Db 121 IVHPTPIRAGDGRHLLTLEDFHDLFYHLEQVNTYOMHGGQREYFGLTPDET 180
 QY 181 LGTITMCPPTWAKESAPYMCRAVKTLPDRITWT 211
 Db 181 LGTITMCPPTWAKESAPYMCRAVKTLPDRITWT 211

RESULT 4
 AAU76916
 ID AAU76916 standard; Protein; 484 AA.
 XX
 AC AAU76916;

XX 05-JUN-2002 (first entry)
 DT Human zcytoril/IgGgamma1 fusion protein with Glu-Glu tag.
 XX
 DE 2-Cytor II; human; cytokine receptor; atopy; psoriasis;
 XX interleukin-T-cell inducible factor; IL-TIF; allergy; asthma;
 KW receptor-modulated apoptosis; Th1; immune response; pancreatitis;
 KW type I diabetes; IDDM; pancreatic cancer; Graves disease; SLE;
 KW inflammatory bowel disease; IBD; Crohn's disease; colon cancer;
 KW intestinal cancer; diverticulosis; autoimmune disease; sepsis;
 KW multiple sclerosis; MS; systemic lupus erythematosus;
 KW myasthenia gravis; rheumatoid arthritis; kidney dysfunction.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX WO200212345-A2.
 XX 14-FEB-2002.
 PD
 XX 08-AUG-2001; 2001WO-US24838.
 XX
 PR 08-AUG-2000; 2000US-223827P.
 PR 01-DEC-2000; 2000US-250876P.
 XX (ZYMO) ZYMOGENETICS INC.
 PA Kindvogel WR, Topouzis S;
 PI Kindvogel WR, Topouzis S;
 DR WPI: 2002-217182/27.
 DR N-PSDB; ABK10522.
 XX
 PT New soluble cytokine receptor which binds interleukin-T-cell inducible
 PT factor and antagonizes its activity in inflammatory and immune diseases
 PT such as cancer, diabetes, asthma, sepsis, psoriasis and autoimmune
 PT diseases
 PT
 XX Example 7; Page 113-114; 117pp; English.
 CC This invention relates to the protein and cDNA sequences of a novel
 CC soluble cytokine receptor polypeptide designated zcytoril, which binds
 CC interleukin-T-cell inducible factor (IL-TIF) or antagonizes IL-TIF
 CC activity. The protein of the invention is useful for reducing IL-TIF-
 CC or IL-9 induced inflammation, and inhibiting IL-TIF-induced
 CC proliferation. The protein is also useful for suppressing an immune
 CC response in a mammal exposed to an antigen or pathogen. Soluble zcytoril
 CC receptor or heterodimeric polypeptide is useful for enhancing the in
 CC vivo killing of target tissues by directly stimulating a zcytoril
 CC receptor-modulated apoptotic pathway. IL-TIF is involved in promoting
 CC Th1-type immune responses and antagonists of IL-TIF have beneficial use
 CC against diseases involving such immune responses. Soluble zcytoril
 CC heterodimers are useful as antagonists in inflammatory and immune
 CC diseases or conditions such as pancreatitis, type I diabetes (IDDM),
 CC Crohn's disease, colon and intestinal cancer, diverticulosis, autoimmune
 CC disease (e.g. IDDM, multiple sclerosis (MS), systemic lupus
 CC erythematosus (SLE), myasthenia gravis, rheumatoid arthritis and IBD),
 CC sepsis, asthma, allergy and other atopic diseases, psoriasis and kidney
 CC dysfunction. Soluble zcytoril receptor or heterodimeric receptor
 CC polypeptides are useful in vivo or in diagnostic applications to detect
 CC IL-TIF expressing cancers in vivo or in tissue samples and to prepare
 CC an antagonizing Mab inhibits cancer growth and targets immune-mediated
 CC killing. The present sequence represents the zcytoril/IgG1 fusion
 CC protein of the invention
 CC
 XX Sequence 484 AA;
 SQ
 Query Match 100.0%; Score 1142; DB 23; Length 484;
 Best Local Similarity 100.0%; Pred. No. 1.2e-120;
 Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

us-09-728-911-34.rag

Mon Jan 13 15:37:34 2003

QY 1 PEDPSDLLQHVKFOSSNFENILTWDSGPEPTPTVYSIEYKTYGERDVAKKGCORITRK 60
 DB 18 PEDPSDLLQHVKFOSSNFENILTWDSGPEPTPTVYSIEYKTYGERDVAKKGCORITRK 77
 QY 61 SCNLTVETGNLTLYARVAVTAVSAGRSATKMTDRFSSLOHTTLKPPDVTCISKVRSIQM 120
 DB 78 SCNLTVETGNLTLYARVAVTAVSAGRSATKMTDRFSSLOHTTLKPPDVTCISKVRSIQM 137
 QY 121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELVQVNTYQMHGKGKQREYEFFGLTPDTEF 180
 DB 138 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELVQVNTYQMHGKGKQREYEFFGLTPDTEF 197
 QY 181 LGTMMICVPTWAKESAPYMCVKTLPORTWT 211
 DB 198 LGTMMICVPTWAKESAPYMCVKTLPORTWT 228
 RESULT 5
 ID AAW97861 standard; Protein; 574 AA.
 AC AAW97861;
 XX 07-JUN-1999 (first entry)
 DT Human cytokine receptor 11 (Zcytor11).
 DE Cytokine receptor 11; Zcytor11; human; pancreas; small intestine;
 KW colon; thymus.
 XX Homo sapiens.
 XX Key
 FH Peptide
 FT /note= "signal peptide"
 FT /note= "mature protein"
 FT Domain
 FT /note= "extracellular domain, this region is
 FT specifically claimed in Claim 20"
 FT 229..251
 FT /note= "transmembrane domain"
 FT 252..574
 FT /note= "intracellular domain"
 FT 1..228
 FT /note= "this polypeptide is specifically claimed
 FT in Claim 27"
 FT 1..251
 FT /note= "this polypeptide is specifically claimed
 FT in Claim 27"
 FT 1..574
 FT /note= "this polypeptide is specifically claimed
 FT in Claim 27"
 FT 2..228
 FT /note= "this polypeptide is specifically claimed
 FT in Claim 27"
 FT 2..551
 FT /note= "this polypeptide is specifically claimed
 FT in Claim 27"
 FT 2..574
 FT /note= "this polypeptide is specifically claimed
 FT in Claim 27"
 PN WO9907848-A1.
 XX 18-FEB-1999.
 XX 30-JUL-1998; 98WO-US15847.
 XX 05-AUG-1997; 97US-0906713.
 XX (ZYMO) ZYMOGENETICS INC.

PI Adams RL, Farrah TM, Jelmsberg AC, Lok S, Whitmore TE;
 XX WPI; 1999-167425/14.
 DR N-PSDB; AAX24379.
 XX Novel human cytokine receptor Zcytor11 - useful for screening for
 FT ligands to modulate or promote proliferation and/or differentiation
 PT of e.g. pancreatic or colon tissue
 XX Claim 27; Page 54-56; 62pp; English.
 PS This is the amino acid sequence of human cytokine receptor 11
 CC (Zcytor11), a novel class II cytokine receptor that appears to be a
 CC receptor for a helical cytokine of the interferon/interleukin-10
 CC class. The sequence was deduced from the nucleotide sequence (see
 CC AAX24379) of a cDNA clone obtained from pancreatic islet cDNA
 CC library. Zcytor11 is a cell surface receptor that is expressed in
 CC pancreas, small intestine, colon and thymus. Novel Zcytor11
 CC polypeptides, especially an extracellular domain (see AAW97864) of
 CC Zcytor11, can be used to detect ligands that promote the
 CC proliferation and/or differentiation of these organs. The
 CC invention provides claimed expression vectors and transformed or
 CC transfected cells, as well as an antibody that specifically binds
 CC to the extracellular domain of Zcytor11, and an anti-idiotypic
 CC antibody. The vectors include a promoter, a terminator and DNA
 CC encoding the extracellular domain, signal sequence, transmembrane
 CC domain or intracellular domain of Zcytor11.
 XX Sequence 574 AA;
 SQ Query Match 100.0%; Score 1142; DB 20; Length 574;
 Best Local Similarity 100.0%; Pred. NO. 1.5e-120;
 Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 PEDPSDLLQHVKFOSSNFENILTWDSGPEPTPTVYSIEYKTYGERDVAKKGCORITRK 60
 DB 18 PEDPSDLLQHVKFOSSNFENILTWDSGPEPTPTVYSIEYKTYGERDVAKKGCORITRK 77
 QY 61 SCNLTVETGNLTLYARVAVTAVSAGRSATKMTDRFSSLOHTTLKPPDVTCISKVRSIQM 120
 DB 78 SCNLTVETGNLTLYARVAVTAVSAGRSATKMTDRFSSLOHTTLKPPDVTCISKVRSIQM 137
 QY 121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELVQVNTYQMHGKGKQREYEFFGLTPDTEF 180
 DB 138 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELVQVNTYQMHGKGKQREYEFFGLTPDTEF 197
 QY 181 LGTMMICVPTWAKESAPYMCVKTLPORTWT 211
 DB 198 LGTMMICVPTWAKESAPYMCVKTLPORTWT 228
 RESULT 6
 ID AAW97045 standard; Protein; 574 AA.
 AC AAW97045;
 XX 31-OCT-2000 (first entry)
 DT Human TANGO 241.
 DE TANGO 241; transmembrane; class II; cytokine receptor; chromosome 1p36;
 KW cytostatic; cerebroprotective; immunomodulatory; anti-inflammatory;
 KW virucide; antibacterial; vasotropic.
 XX Homo sapiens.
 XX Key
 FH Active-site
 FT /label= Signal_peptide
 FT /label= Mature_protein
 FT /label= Mature_protein
 FT Domain

```

FT FT /label= Extracellular_domain
FT Domain 38..105
FT /label= Fibronectin_III_domain
FT Modified-site 80
FT /note= "N-linked glycosylation site"
FT Modified-site 87
FT /note= "N-linked glycosylation site"
FT Modified-site 172
FT /note= "N-linked glycosylation site"
FT Domain 227..251
FT /label= Transmembrane_domain
FT Domain 252..574
FT /label= Cytoplasmic_domain
FT Misc-difference 372..381
FT /label= Box-3-like_element
FT /note= "Involved in STAT binding"
XX XX
XX WO200039161-A1.
XX
XX 06-JUL-2000.
XX
XX 30-DEC-1999; 99WO-US31328.
XX
XX 31-DEC-1999; 98US-0224669.
XX
XX (MILL-) MILLENNIUM PHARM INC.
XX
XX Busfield SJ;
XX
XX WPI; 2000-453372/39.
XX
XX N-PSDB; AAA51869, AAA51870.
XX
XX New nucleic acid molecules encoding polypeptides designated TANGO 241
XX and TANGO 242 used for treating e.g. brain and pancreatic disorders
XX
XX Claim 8; Fig 1A-B; 127pp; English.
XX
XX Novel transmembrane proteins, designated TANGO 241 and TANGO 242, are
XX members of the class II cytokine receptor superfamily. The TANGO 241 and
XX 242 genes have been localized to human chromosomes 1p36 and 3q21,
XX respectively. The proteins, cDNA and their modulators can be used for the
XX treatment of viral and bacterial infection, inflammatory and autoimmune
XX disorders, vascular injury and inhibition of angiogenesis. In particular,
XX TANGO 241 can be used to treat pancreatic disorders and TANGO 242 can be
XX used to treat brain disorders.
XX
XX Sequence 574 AA:
SQ
XX
XX Query Match 100.0%; Score 1142; DB 21; Length 574;
XX Best Local Similarity 100.0%; Pred. No. 1.5e-120;
XX Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 PEDPSDLLQHVKFOSSNFENILTWDSGPEGTPTVYSIEYKTYGSRDVAKKGCORITRK 60
XX 18 PEDPSDLLQHVKFOSSNFENILTWDSGPEGTPTVYSIEYKTYGSRDVAKKGCORITRK 77
XX
XX 61 SCULVETGNLTELVAARVAVASAGRSATKMTDRFSSLOHTTLKPPDVTICISKRSIQM 120
XX 78 SCULVETGNLTELVAARVAVASAGRSATKMTDRFSSLOHTTLKPPDVTICISKRSIQM 137
XX
XX 121 IVHPTPTIRAGDGRHLTLEDIFHDLFYHLELOVNRRTYOMHLGGKOREYFFGLTPDTEF 180
XX 138 IVHPTPTIRAGDGRHLTLEDIFHDLFYHLELOVNRRTYOMHLGGKOREYFFGLTPDTEF 197
XX
XX 181 LGTIMICVPTMAKESAPYMCRAVKTLPDRTWT 211
XX 198 LGTIMICVPTMAKESAPYMCRAVKTLPDRTWT 228
XX
XX RESULT 7
XX ID AAB62665
XX AC AAB62665 standard; Protein: 574 AA.
XX

```

```

AC AAB62665;
XX
XX 10-SEP-2001 (first entry)
XX
XX Human ZCYTO18 receptor protein, zcytor11.
XX
XX Human; cytosolic; cytokine; ZCYTO18 protein; genetic abnormality;
XX cancer; inflammation; gene therapy; zcytor11.
XX
XX Homo sapiens.
XX
XX WO200146422-A1.
XX
XX 28-JUN-2001.
XX
XX 22-DEC-2000; 2000WO-US35308.
XX
XX 23-DEC-1999; 99US-0471767.
XX
XX 01-DEC-2000; 2000US-0250841.
XX
XX (ZYMO ) ZYMOGENETICS INC.
XX
XX Presnell SR, Kindsvogel W;
XX
XX WPI; 2001-408648/43.
XX
XX N-PSDB; AAD09732.
XX
XX Novel human cytokine polypeptide, ZCYTO18, useful for treating cancer -
XX Claim 1; Page 151-153; 167pp; English.
XX
XX The patent discloses novel human cytokine, ZCYTO18 protein and its
XX corresponding DNA. ZCYTO18 protein induces proliferation of cells
XX expressing zcytor11, a receptor for ZCYTO18 or induces cytotoxicity
XX in K562 cells. ZCYTO18 DNA is useful for detecting a genetic
XX abnormality in a patient. ZCYTO18 DNA and its antibodies are useful
XX for detecting cancer and inflammation. ZCYTO18 protein is useful for
XX killing cancer cells. It is useful for increasing platelets in a
XX patient or injured tissue. It is also used in gene therapy.
XX The present sequence is human zcytor11, which is a receptor for
XX ZCYTO18 protein.
XX
XX Sequence 574 AA:
SQ
XX
XX Query Match 100.0%; Score 1142; DB 22; Length 574;
XX Best Local Similarity 100.0%; Pred. No. 1.5e-120;
XX Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 PEDPSDLLQHVKFOSSNFENILTWDSGPEGTPTVYSIEYKTYGSRDVAKKGCORITRK 60
XX 18 PEDPSDLLQHVKFOSSNFENILTWDSGPEGTPTVYSIEYKTYGSRDVAKKGCORITRK 77
XX
XX 61 SCULVETGNLTELVAARVAVASAGRSATKMTDRFSSLOHTTLKPPDVTICISKRSIQM 120
XX 78 SCULVETGNLTELVAARVAVASAGRSATKMTDRFSSLOHTTLKPPDVTICISKRSIQM 137
XX
XX 121 IVHPTPTIRAGDGRHLTLEDIFHDLFYHLELOVNRRTYOMHLGGKOREYFFGLTPDTEF 180
XX 138 IVHPTPTIRAGDGRHLTLEDIFHDLFYHLELOVNRRTYOMHLGGKOREYFFGLTPDTEF 197
XX
XX 181 LGTIMICVPTMAKESAPYMCRAVKTLPDRTWT 211
XX 198 LGTIMICVPTMAKESAPYMCRAVKTLPDRTWT 228
XX
XX RESULT 8
XX ID AAB62665
XX AC AAB62665 standard; Protein: 574 AA.
XX
XX 23-JUL-2001 (first entry)
XX

```


DE Human zcytor11 receptor.

XX Cytokine receptor; zcytor16; IL-TIF; antiinflammatory; cytostatic;

KW antirheumatic; antiarthritic; antiasthmatic; antiatherosclerotic;

KW immunosuppressive; chromosome 6q24.1-25.2; human; zcytor11.

XX Homo sapiens.

OS WO200140467-A1.

FN 07-JUN-2001.

XX 01-DEC-2000; 2000WO-US32703.

XX 03-DEC-1999; 99US-0169049.

PR 13-SEP-2000; 2000US-0232219.

PR 31-OCT-2000; 2000US-0244610.

XX (ZYMO) ZYMOGENETICS INC.

PA Presnell SR, Xu W, Kindsvogel W, Chen Z;

XX WPI: 2001-356158/37.

DR N-PSDB; AAF83750.

XX New soluble cytokine receptor polypeptides and polynucleotides, useful

PT for diagnosing and treating cancer and inflammatory conditions -

XX Example 13; Page 202-204; 210pp; English.

XX The invention relates to a human cytokine receptor polypeptide,

CC designated zcytor16. The zcytor16 polypeptide can be expressed by

CC standard recombinant methodology and can bind to IL-TIF (undefined). The

CC zcytor16 protein is useful for: inhibiting IL-TIF induced proliferation

CC or differentiation of hematopoietic cell(s) (progenitors); reducing

CC IL-TIF induced or IL-9 induced inflammation; and suppressing an

CC inflammatory response in a mammal with inflammation. Heteromeric/

CC multimeric receptor polypeptides such as soluble zcytor 16/CRF2-4 can be

CC used to reduce progression and symptoms of cancer. Zcytor16 polypeptides

CC can also be used to detect IL-TIF levels which is indicative of

CC pathological conditions including inflammatory states (e.g. rheumatoid

CC arthritis) and cancer. Antibodies that bind zcytor16 polypeptides and the

CC polypeptides themselves are useful for the treatment of inflammation,

CC inflammatory diseases (e.g. infection, asthma, inflammatory bowel

CC disease, rheumatoid arthritis and atherosclerosis) and autoimmune

CC diseases. The antibodies and zcytor16 polynucleotides are also useful

CC for detecting cancer. The present sequence represents the human zcytor11

CC receptor protein.

XX XX

SQ Sequence 574 AA;

Query Match 100.0%; Score 1142; DB 22; Length 574;

Best Local Similarity 100.0%; Pred. No. 1.5e-120;

Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PEDPSDLLQHVKQSSNFENILTWDSGPEPTPTVYSIEYKTYGERDVAKKGCORITRK 60

DB 18 PEDPSDLLQHVKQSSNFENILTWDSGPEPTPTVYSIEYKTYGERDVAKKGCORITRK 77

QY 61 SCNLTVETGNLTLYYARVAVSAGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120

DB 78 SCNLTVETGNLTLYYARVAVSAGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 137

QY 121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRVYQMHLLGKQREYEFFGLTPTDTEF 180

DB 138 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRVYQMHLLGKQREYEFFGLTPTDTEF 197

QY 181 LGTIMITCVPTWAKESAPYMCVKTLTPDRTWT 211

DB 198 LGTIMITCVPTWAKESAPYMCVKTLTPDRTWT 228

RESULT 9

AAB87607

ID AAB87607 standard; Protein; 574 AA.

XX AAB87607;

AC 15-MAY-2001 (first entry)

DT Human PRO20233.

DE Human; PRO protein; mapping.

XX Homo sapiens.

OS WO200116318-A2.

FN 08-MAR-2001.

XX 24-AUG-2000; 2000WO-US23328.

XX 01-SEP-1999; 99WO-US20111.

PR 15-SEP-1999; 99WO-US21090.

PR 07-DEC-1999; 99US-0169495.

PR 09-DEC-1999; 99US-0170262.

PR 11-JAN-2000; 2000US-0175481.

PR 18-FEB-2000; 2000WO-US04341.

PR 18-FEB-2000; 2000WO-US04342.

PR 22-FEB-2000; 2000WO-US04414.

PR 01-MAR-2000; 2000WO-US05601.

PR 03-MAR-2000; 2000US-0187202.

PR 25-APR-2000; 2000US-0199397.

PR 22-MAY-2000; 2000WO-US14042.

PR 05-JUN-2000; 2000US-0209832.

XX (GETH) GENENTECH INC.

PA Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

XX Grimaldi CJ, Gurney AL, Watanabe CK, Wood WI;

PI WPI: 2001-183260/18.

XX N-PSDB; AAF92139.

DR Eighty four nucleic acids encoding PRO polypeptides, useful in

XX molecular biology, including use as hybridization probes, and in

PT chromosome and gene mapping. -

XX Claim 12; Fig 164; 278pp; English.

PS The present sequence is a human PRO polypeptide (secreted and

XX transmembrane). The PRO protein, and PRO agonists, PRO antagonists or

CC anti-PRO antibodies are useful for preparation of a medicament useful in

CC the treatment of a condition which is responsive to the PRO protein,

CC agonists, antagonists or anti-PRO antibodies. The PRO protein may also be

CC employed as molecular weight markers for protein electrophoresis. The PRO

CC coding sequence has applications in molecular biology, including use as

CC hybridisation probes, and in chromosome and gene mapping.

XX SQ

Query Match 100.0%; Score 1142; DB 22; Length 574;

Best Local Similarity 100.0%; Pred. No. 1.5e-120;

Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PEDPSDLLQHVKQSSNFENILTWDSGPEPTPTVYSIEYKTYGERDVAKKGCORITRK 60

DB 18 PEDPSDLLQHVKQSSNFENILTWDSGPEPTPTVYSIEYKTYGERDVAKKGCORITRK 77

QY 61 SCNLTVETGNLTLYYARVAVSAGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120

DB 78 SCNLTVETGNLTLYYARVAVSAGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 137

QY 121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRVYQMHLLGKQREYEFFGLTPTDTEF 180

DB 138 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRVYQMHLLGKQREYEFFGLTPTDTEF 197

QY 181 LGTITMVCPTWAKESAPYMCRCVKTLPPDRTWT 211
 DB 198 LGTITMVCPTWAKESAPYMCRCVKTLPPDRTWT 228

RESULT 10
 AAU76905
 ID AAU76905 standard; Protein; 574 AA.
 AC AAU76905;
 DT 05-JUN-2002 (first entry)
 DE Human Z-cytoc-II protein.

KM Z-cytoc II; human; cytokine receptor; atopy; psoriasis;
 KM Interleukin-T-cell inducible factor; IL-TIF; allergy; asthma;
 KM receptor-modulated apoptosis; Th1; immune response; pancreatitis;
 KM type I diabetes; IDDM; pancreatic cancer; Graves disease; SLE;
 KM inflammatory bowel disease; IBD; Crohn's disease; colon cancer;
 KM intestinal cancer; diverticulosis; autoimmune disease; sepsis;
 KM multiple sclerosis; MS; systemic lupus erythematosus;
 KM myasthenia gravis; rheumatoid arthritis; kidney dysfunction.

OS Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FH Region 17..228
 FT /note= "Soluble extracellular domain"
 XX
 XX MO200212345-A2.
 PD 14-FEB-2002.
 XX
 PF 08-AUG-2001; 2001WO-US24838.
 XX
 PR 08-AUG-2000; 2000US-223827P.
 PR 01-DEC-2000; 2000US-250876P.
 XX
 PA (ZYMO) ZYMOGENETICS INC.
 XX
 PI Kindsvogel WR, Topouzis S;
 DR WPI; 2002-217182/27.
 DR N-PSDB; ABK10501.

PT New soluble cytokine receptor which binds interleukin-T-cell inducible
 factor and antagonizes its activity in inflammatory and immune diseases
 such as cancer, diabetes, asthma, sepsis, psoriasis and autoimmune
 diseases

XX
 XX Example 8; Page 92-94; 117p; English.

CC This invention relates to the protein and cDNA sequences of a novel
 CC soluble cytokine receptor polypeptide designated zcytorII, which binds
 CC interleukin-T-cell inducible factor (IL-TIF) or antagonizes IL-TIF
 CC activity. The protein of the invention is useful for reducing IL-TIF-
 CC or IL-9 induced inflammation, and inhibiting IL-TIF-induced
 CC proliferation. The protein is also useful for suppressing an immune
 CC response in a mammal exposed to an antigen or pathogen. Soluble zcytorII
 CC receptor or heterodimeric polypeptide is useful for enhancing the in
 CC vivo killing of target tissues by directly stimulating a zcytorII
 CC receptor-modulated apoptotic pathway. IL-TIF is involved in promoting
 CC Th1-type immune responses and antagonists of IL-TIF have beneficial use
 CC against diseases involving such immune responses. Soluble zcytorII
 CC heterodimers are useful as antagonists in inflammatory and immune
 CC diseases or conditions such as pancreatitis, type I diabetes (IDDM),
 CC pancreatic cancer, Graves disease, inflammatory bowel disease (IBD),
 CC Crohn's disease, colon and intestinal cancer, diverticulosis, autoimmune
 CC disease (e.g. IDDM), multiple sclerosis (MS), systemic lupus
 CC erythematosus (SLE), myasthenia gravis, rheumatoid arthritis and IBD),
 CC sepsis, asthma, allergy and other atopic diseases, psoriasis and kidney

CC dysfunction. Soluble zcytorII receptor or heterodimeric receptor
 CC polypeptides are useful in vivo or in diagnostic applications to detect
 CC IL-TIF expressing cancers in vivo or in tissue samples and to prepare
 CC antibodies. ZcytorII serves as a target for Mab therapy of cancer where
 CC an antagonising Mab inhibits cancer growth and targets immune-mediated
 CC killing. The present sequence represents the zcytorII protein of the
 CC invention

XX
 XX SQ Sequence 574 AA;
 XX
 XX Query Match 100.0%; Score 1142; DB 23; length 574;
 XX Best Local Similarity 100.0%; Pred. No. 1.5e-120;
 XX Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PEDPSDLQHVAFQSSNFENILTMDSGEGPDPTVYSIEYKTERGVMAKKGORTRK 60
 DB 18 PEDPSDLQHVAFQSSNFENILTMDSGEGPDPTVYSIEYKTERGVMAKKGORTRK 77
 QY 61 SCNLVETGNLTLYAAVAVTAVSAGRSATYMTDRFSSLOHTLKPDPVTCISKVRSIQM 120
 DB 78 SCNLVETGNLTLYAAVAVTAVSAGRSATYMTDRFSSLOHTLKPDPVTCISKVRSIQM 137
 QY 121 IVHPTPTPIRAGDGRHLTLEDIFHDLFYHLELVQVNRITYOMHLGGKOREYFPGITPDTF 180
 DB 138 IVHPTPTPIRAGDGRHLTLEDIFHDLFYHLELVQVNRITYOMHLGGKOREYFPGITPDTF 197

QY 181 LGTITMVCPTWAKESAPYMCRCVKTLPPDRTWT 211
 DB 198 LGTITMVCPTWAKESAPYMCRCVKTLPPDRTWT 228

RESULT 11
 AAU78083
 ID AAU78083 standard; Protein; 574 AA.
 XX
 XX AAU78083;
 XX
 DT 05-JUN-2002 (first entry)
 XX
 DE Human interleukin 22 receptor (IL-22R) protein sequence.

KM Interleukin 22; IL-22; cytostatic; antiinflammatory; IL-22 antagonist;
 KM immunotherapy; PAP1; pancreatitis associated protein; receptor;
 KM IL-22R; IL-10Rbeta; bioactive molecule linkage; cell death; pancreatitis;
 KM pancreatic disorder; pancreatic carcinoma; acinar cell carcinoma; human;
 KM mixed cell population pancreatic carcinoma.

XX
 XX Homo sapiens.
 OS
 XX
 XX WO200216611-A2.
 XX
 PD 28-FEB-2002.
 XX
 PF 30-MAY-2001; 2001WO-US17443.
 XX
 PR 24-AUG-2000; 2000WO-US23328.
 XX
 PA (GENTECH) GENE-TECH INC.
 XX
 PI Aggarwal S, Foster JS, Goddard A, Gurney AL, Marucka EM, Wood WI;
 PI Xie M;
 DR WPI; 2002-280940/32.

PT Novel isolated interleukin 22 polypeptide useful for identifying IL-22
 PT agonists and antagonists that are used for treating acute pancreatitis,
 PT chronic pancreatitis, pancreatic carcinoma

XX
 XX Example 2; Fig 11; 94pp; English.

CC The present invention relates to a new polypeptide having at least 80%
 CC identity to a 101 amino acid interleukin (IL)-22 sequence. The invention
 CC is useful for detecting IL-22R (IL-22 receptor) or IL-10Rbeta polypeptide

CC in a sample which involves contacting sample with an IL-22 polypeptide
 CC and determining the formation of an IL-22R/IL-22 polypeptide conjugate or
 CC an IL-10Rbeta/IL-22 polypeptide conjugate. Preferably, the IL-22
 CC polypeptide is labelled with a detectable label or is attached to a solid
 CC support. The polypeptide is also useful for linking a bioactive molecule,
 CC e.g. toxin, radiolabel or antibody that causes the death of the cell, to
 CC a cell expressing IL-22R polypeptide or IL-10Rbeta polypeptide which
 CC involves contacting the cell with IL-22 polypeptide that is bound to the
 CC bioactive molecule and allowing binding of the IL-22 polypeptide with
 CC IL-22R or IL-10Rbeta polypeptide thus linking the bioactive molecules to
 CC the cell. The molecules of the invention can also be used for modulating
 CC biological activity of cell expressing IL-22R or IL-10Rbeta polypeptide,
 CC whereby the cell is killed and the antibody of the invention is useful
 CC for inhibiting IL-22 induced expression of PAP1 (pancreatitis associated
 CC protein) by pancreatic cells. The antibody is also useful for treating a
 CC pancreatic disorder such as acute or chronic pancreatitis, pancreatic
 CC carcinoma including acinar cell carcinoma or mixed cell population
 CC of the pancreas in a mammal. The present amino acid sequence represents
 CC the human interleukin 22 receptor (IL-22R) protein of the invention.
 CC This sequence forms a receptor/ligand interaction with IL-22.
 XX
 SQ

Query Match 100.0%; Score 1142; DB 23; Length 574;
 Best Local Similarity 100.0%; Pred. No. 1.5e-120;
 Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PEDPSDLLQHVAFQSSNFENILTWDSGPGTPTVYSIEYKTYGERDVAKKGCQRIIRK 60
 DB 18 PEDPSDLLQHVAFQSSNFENILTWDSGPGTPTVYSIEYKTYGERDVAKKGCQRIIRK 77

QY 61 SCNLTVETGNLTLYYARVAVSAGRSATKMTDRFSSLOHTTLKPPDVTICISKVRSIQM 120
 DB 78 SCNLTVETGNLTLYYARVAVSAGRSATKMTDRFSSLOHTTLKPPDVTICISKVRSIQM 137

QY 121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELVQVNRVYOMHLLGGKQREYFPGTPTDEF 180
 DB 138 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELVQVNRVYOMHLLGGKQREYFPGTPTDEF 197

QY 181 LGTIMICVPTWAKESAPYMCVRKTLPPDRWT 211
 DB 198 LGTIMICVPTWAKESAPYMCVRKTLPPDRWT 228

RESULT 12
 ID AAM24345 standard; Protein; 196 AA.
 AC AAM24345;
 DT 12-OCT-2001 (first entry)
 XX Human EST encoded protein SEQ ID NO: 1870.
 DE
 XX Human; sheep; pig; cow; fruit fly; yeast; hamster; macaque; horse;
 KW tomato; monkey; dog; sea urchin; expressed sequence tag; EST;
 KW diagnostics; forensic test; gene mapping; genetic disorder;
 KW biodiversity; gene therapy; nutrition.
 XX
 OS Homo sapiens.
 XX
 PN WO200154477-A2.
 XX
 PD 02-AUG-2001.
 XX
 PF 25-JAN-2001; 2001WO-US02687.
 XX
 XX 25-JAN-2000; 2000US-0491404.
 PR 17-JUL-2000; 2000US-0617746.
 PR 03-AUG-2000; 2000US-0631451.
 PR 15-SEP-2000; 2000US-0663870.
 XX

PA (HYSE-) HYSEQ INC.
 XX Tang YT, Liu C, Zhou P, Qian XB, Wang Z, Chen R, Asundi V;
 PI Cao Y, Drmanac RA, Zhang J, Werhman T;
 XX WPI: 2001-476164/51.
 DR N-PSDB; AAH99004.
 XX Isolated polypeptide for treatment of diseases, diagnostics, raising
 PT antibodies and research use -
 PT
 PS Claim 20; Page 1210; 1275pp; English.

CC The present invention provides the protein and coding sequences of novel
 CC proteins from a variety of organisms, including human, dog, cat, horse,
 CC cow, pig, hamster, monkey, macaque, yeast, bacteria, fruit fly, sea
 CC urchin and tomato. These were derived from expressed sequence tags (ESTs)
 CC from the organism of interest. They can be used in diagnostics,
 CC forensics, gene mapping, identification of mutations, to assess
 CC biodiversity and for nutritional purposes. The present sequence is a
 CC protein of the invention.
 XX
 SQ Sequence 196 AA;

Query Match 74.8%; Score 854; DB 22; Length 196;
 Best Local Similarity 100.0%; Pred. No. 1.6e-88;
 Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PEDPSDLLQHVAFQSSNFENILTWDSGPGTPTVYSIEYKTYGERDVAKKGCQRIIRK 60
 DB 18 PEDPSDLLQHVAFQSSNFENILTWDSGPGTPTVYSIEYKTYGERDVAKKGCQRIIRK 77

QY 61 SCNLTVETGNLTLYYARVAVSAGRSATKMTDRFSSLOHTTLKPPDVTICISKVRSIQM 120
 DB 78 SCNLTVETGNLTLYYARVAVSAGRSATKMTDRFSSLOHTTLKPPDVTICISKVRSIQM 137

QY 121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELVQVNRVYOM 160
 DB 138 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELVQVNRVYOM 177

RESULT 13
 ID AAY97047 standard; Protein; 353 AA.
 AC AAY97047;
 DT 31-OCT-2000 (first entry)
 XX Partial murine TANGO 241.
 DE
 XX TANGO 241; transmembrane; class II; cytokine receptor; cytostatic;
 KW cerebroprotective; immunomodulatory; anti-inflammatory; virucide;
 KW antibacterial; vasotropic.
 XX
 OS Mus sp.
 XX
 PN WO200039161-A1.
 XX
 PD 06-JUL-2000.
 XX
 PF 30-DEC-1999; 99WO-US31328.
 XX
 PR 31-DEC-1998; 98US-0224669.
 XX
 PA (MILL-) MILLENNIUM PHARM INC.
 XX
 PI Busfield SJ;
 XX
 XX WPI: 2000-452372/39.
 DR N-PSDB; AAA51873, AAA51874.
 XX
 PT New nucleic acid molecules encoding polypeptides designated TANGO 241

PT and TANGO 242 used for treating e.g. brain and pancreatic disorders
 XX Disclosure; Fig 7A-B; 127pp; English.
 XX
 CC Novel transmembrane proteins, designated TANGO 241 and TANGO 242, are
 CC members of the class II cytokine receptor superfamily. The TANGO 241 and
 CC 242 genes have been localized to human chromosomes 1p36 and 3q21,
 CC respectively. The proteins, cDNA and their modulators can be used for the
 CC treatment of viral and bacterial infection, inflammatory and autoimmune
 CC disorders, vascular injury and inhibition of angiogenesis. In particular,
 CC TANGO 241 can be used to treat pancreatic disorders and TANGO 242 can be
 CC used to treat brain disorders.
 XX
 SQ Sequence 353 AA;

Query Match Best Local Similarity 60.5%; Score 691; DB 21; Length 353;
 Matches 128; Conservative 13; Mismatches 22; Indels 0; Gaps 0;

OY 48 WAKKSCORITRKSCLNLTVEITGNTLEYARVAVSAGSGSATMDRFSLSLOHTTLKRP 107
 DB 1 WLAKGSCORITRKSCLNLTVEITGNTLEYARVAVSAGSGSATMDRFSLSLOHTTLKRP 60
 OY 108 DVTCTSKRSTOMIVHPPTPIRAGDGRHLLTLEDFHDLFYHLELOVNRTOYQMHGSKOR 167
 DB 61 DVTCTSKRSTOMIVHPPTPIRAGDGRHLLTLEDFHDLFYHLELOVNRTOYQMHGSKOR 120
 OY 168 EYEFPGILPTDEFGITMICYPTAKESAPYKCRVKTLPDRTW 210
 DB 121 EYEFPGILPTDEFGITMICYPTAKESAPYKCRVKTLPDRTW 163

RESULT 14
 ID AAB62663 standard; Protein; 210 AA.
 XX AAB62663;

XX 23-JUL-2001 (first entry)

DE Human zcytor16 extracellular domain fragment (residues 22-231).

KM Cytokine receptor; zcytor16; IL-TIF; antiinflammatory; cytostatic;
 KW antiinflammatory; antiarthritic; antiasthmatic; antithrombotic;
 XX immunosuppressive; chromosome 6q24.1-25.2; human.

OS Homo sapiens.

XX MO200140467-A1.

PD 07-JUN-2001.

PF 01-DEC-2000; 2000WO-US32703.

XX 03-DEC-1999; 99US-0168046.

PR 13-SEP-2000; 2000US-0232219.

XX 31-OCT-2000; 2000US-024610.

PA (ZYMO) ZYMOGENETICS INC.

PI Presnell SR, Xu W, Kindsvogel W, Chen Z;

DR WPI; 2001-356158/37.

PT New soluble cytokine receptor polypeptides and polynucleotides, useful
 PT for diagnosing and treating cancer and inflammatory conditions -
 XX
 XX Claim 1; Page 193; 210pp; English.

CC The invention relates to a human cytokine receptor polypeptide,
 CC designated zcytor16. The zcytor16 polypeptide can be expressed by
 CC standard recombinant methodology and can bind to IL-TIF (undefined). The
 CC zcytor16 protein is useful for: inhibiting IL-TIF induced proliferation

CC or differentiation of hematopoietic cell(s) (progenitors); reducing
 CC IL-TIF induced or IL-9 induced inflammation; and suppressing
 CC inflammatory response in a mammal with inflammation. Heteromeric/
 CC multimeric receptor polypeptides such as soluble zcytor 16/CR2-4 can be
 CC used to reduce progression and symptoms of cancer. Zcytor16 polypeptides
 CC can also be used to detect IL-TIF levels which is indicative of
 CC pathological conditions including inflammatory states (e.g. rheumatoid
 CC arthritis) and cancer. Antibodies that bind zcytor16 polypeptides and the
 CC polypeptides themselves are useful for the treatment of inflammation,
 CC inflammatory diseases (e.g. infection, asthma, inflammatory bowel
 CC disease, rheumatoid arthritis and atherosclerosis) and autoimmune
 CC diseases. The antibodies and zcytor16 polynucleotides are also useful
 CC for detecting cancer. The present sequence represents the human zcytor16
 CC extracellular domain fragment.

SQ Sequence 210 AA;

Query Match Best Local Similarity 23.0%; Score 263; DB 22; Length 210;
 Matches 66; Conservative 29; Mismatches 87; Indels 12; Gaps 4;

OY 9 QHVFQSSNFENILTMDSGEPTPD-TVYSIEKTYGERDWAQKQGRITRKSCLNLTVE 67
 DB 11 QVQFQSSNFENILTMDSGEPTPD-TVYSIEKTYGERDWAQKQGRITRKSCLNLTVE 70
 OY 68 TGNLTLYARVAVSAGSGSATMDRFSLSLOHTTLKRPDVTCTSKRSTOMIVHPPT 127
 DB 71 TSDIQEYGRVAVSAGSGSATMDRFSLSLOHTTLKRPDVTCTSKRSTOMIVHPPT 130
 OY 128 PIRAGDGRHLLTLEDFHDLFYHLELOVNRTOYQMHGSKOR 181
 DB 131 PYRQKKNVSIED-YELLYRVFIINSLKEKQKYE---GAHRAVEALTPHSSYC 185
 OY 182 GTMICYPTAKES 195
 DB 186 VVAEITQPMIDRRS 199

RESULT 15

ID AAE17319 standard; Protein; 214 AA.

XX AAE17319;

DT 18-APR-2002 (first entry)

DE Human cytokine receptor protein, sbg456548Cytora #1.

KW Human; therapy; wound healing disorder; vaccine; cancer; infection;
 KW autoimmune disorder; hematopoietic disorder; inflammation; arthritis;
 KW Parkinson's disease; Huntington's chorea; schizophrenia; antiarrhythmic;
 KW multiple sclerosis; Alzheimer's disease; analgesic; cardiac; asthma;
 KW ischaemia; stroke; AIDS; bone disease; atherosclerosis; brain disorder;
 KW depression; cardiovascular disease; myocardial infarction; renal failure;
 KW respiratory disease; liver disorder; Fanconi's syndrome; spleen disorder;
 KW type II diabetes mellitus; skeletal muscle disorder; immunosuppressive;
 KW hyperlipidemia; renal disease; hypoglycemia; gastrointestinal disease;
 KW neoplastic; cirrhosis; Hodgkin's disease; neuroleptic; neuroprotective;
 KW haemostatic; vulnary; anticonvulsant; antineoplastic; antiproliferative;
 KW nephrotoxic; hypotensive; vasotropic; cytostatic; cerebroprotective;
 KW allergy; cytokine receptor.

OS Homo sapiens.

XX WO200198342-A1.

PD 27-DEC-2001.

PF 22-JUN-2001; 2001WO-US19929.

XX 22-JUN-2000; 2000US-213156P.

PR 22-JUN-2000; 2000US-213161P.

Search completed: January 13, 2003, 15:30:55
Job time : 31.223 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 13, 2003, 15:31:40 ; Search time 6.68662 Seconds

(without alignments)
612.211 Million cell updates/sec

Title: US-09-728-911-34

Perfect score: 1142

Sequence: 1 PEDPSDLQHVXKFOSSNFEN.....AKESAPYMCVKTLPDRTWT 211

Scoring table:

BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 118974 seqs, 19401057 residues

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database:

1: /cgn2_6/prodata/1/pubppa/US08_NEW_PUB.pep.*
2: /cgn2_6/prodata/1/pubppa/PCT_NEW_PUB.pep.*
3: /cgn2_6/prodata/1/pubppa/US06_NEW_PUB.pep.*
4: /cgn2_6/prodata/1/pubppa/US06_PUBCOMB.pep.*
5: /cgn2_6/prodata/1/pubppa/US07_NEW_PUB.pep.*
6: /cgn2_6/prodata/1/pubppa/US07_PUBCOMB.pep.*
7: /cgn2_6/prodata/1/pubppa/PCTUS_PUBCOMB.pep.*
8: /cgn2_6/prodata/1/pubppa/US08_PUBCOMB.pep.*
9: /cgn2_6/prodata/1/pubppa/US09_NEW_PUB.pep.*
10: /cgn2_6/prodata/1/pubppa/US09_PUBCOMB.pep.*
11: /cgn2_6/prodata/1/pubppa/US10_NEW_PUB.pep.*
12: /cgn2_6/prodata/1/pubppa/US10_PUBCOMB.pep.*
13: /cgn2_6/prodata/1/pubppa/US60_NEW_PUB.pep.*
14: /cgn2_6/prodata/1/pubppa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1142	100.0	211	10	US-09-728-911-34
2	1142	100.0	560	9	US-09-912-672A-5
3	1142	100.0	574	9	US-09-912-672A-2
4	1142	100.0	574	9	US-10-063-547-164
5	1142	100.0	574	10	US-09-728-911-25
6	1142	100.0	574	10	US-09-870-574-4
7	1142	100.0	574	12	US-10-006-867-164
8	1126	98.6	212	9	US-09-912-672A-6
9	691	60.5	353	9	US-09-912-672A-9
10	365	32.0	68	9	US-09-912-672A-9
11	263	23.0	210	10	US-09-728-911-13
12	263	23.0	231	10	US-09-728-911-2
13	263	23.0	231	10	US-09-949-192-6
14	191.5	16.8	217	10	US-09-746-359A-55
15	191.5	16.8	221	10	US-09-746-359A-12
16	191.5	16.8	542	12	US-10-028-072-188
17	191.5	16.8	542	12	US-10-052-586-398
18	191.5	16.8	547	10	US-09-746-359A-54
19	191.5	16.8	553	10	US-09-746-359A-11

20	191.5	16.8	553	10	US-09-949-192-7	Sequence 7, Appli
21	191.5	16.8	571	10	US-09-746-359A-53	Sequence 53, Appli
22	191	16.7	207	10	US-09-746-359A-65	Sequence 65, Appli
23	191	16.7	214	10	US-09-746-359A-63	Sequence 63, Appli
24	191	16.7	559	10	US-09-746-359A-62	Sequence 62, Appli
25	191	16.7	594	10	US-09-746-359A-23	Sequence 23, Appli
26	181	15.8	217	10	US-09-746-359A-38	Sequence 38, Appli
27	181	15.8	514	10	US-09-746-359A-39	Sequence 39, Appli
28	181	15.8	546	10	US-09-746-359A-37	Sequence 37, Appli
29	131.5	11.5	436	10	US-09-240-675-2	Sequence 2, Appli
30	131.5	11.5	557	10	US-09-240-675-4	Sequence 4, Appli
31	128.5	11.3	575	10	US-09-925-300-1672	Sequence 1672, Ap
32	124	10.9	219	10	US-09-355-000-8	Sequence 8, Appli
33	124	10.9	219	10	US-09-355-000-7	Sequence 7, Appli
34	123	10.8	219	10	US-09-355-000-10	Sequence 10, Appli
35	122	10.7	219	10	US-09-355-000-5	Sequence 5, Appli
36	119	10.4	219	10	US-09-355-000-2	Sequence 2, Appli
37	118	10.3	219	10	US-09-355-000-6	Sequence 6, Appli
38	118	10.3	219	10	US-09-355-000-1	Sequence 1, Appli
39	118	10.3	253	10	US-09-355-000-1	Sequence 20, Appli
40	118	10.3	255	10	US-09-103-067-20	Sequence 3, Appli
41	118	10.3	295	10	US-09-103-067-20	Sequence 6, Appli
42	118	10.3	295	10	US-09-949-192-3	Sequence 1, Appli
43	116	10.2	219	10	US-09-355-000-4	Sequence 3, Appli
44	114.5	10.0	150	10	US-09-746-359A-66	Sequence 4, Appli
45	114.5	10.0	211	10	US-09-728-911-36	Sequence 36, Appli

ALIGNMENTS

RESULT 1

US-09-728-911-34

Sequence 34, Application US/09728911

Patent No. US2002001269A1

GENERAL INFORMATION:

APPLICANT: Presnell, Scott R.

APPLICANT: Kindvogel, Wayne

APPLICANT: Chen, Zhi

TITLE OF INVENTION: Human Cytokine Receptor

FILE REFERENCE: 99-93

CURRENT APPLICATION NUMBER: US/09/728,911

PRIOR FILING DATE: 2000-12-01

PRIOR APPLICATION NUMBER: US 60/169,049

PRIOR FILING DATE: 1999-12-03

PRIOR APPLICATION NUMBER: US 60/232,219

PRIOR FILING DATE: 2000-09-13

PRIOR APPLICATION NUMBER: US 60/244,610

NUMBER OF SEQ ID NOS: 36

SOFTWARE: FastSeq for Windows Version 3.0

SEQ ID NO 34

LENGTH: 211

TYPE: PRT

ORGANISM: Homo sapiens

US-09-728-911-34

Query Match 100.0%; Score 1142; DB 10; Length 211;
Best Local Similarity 100.0%; Pred. No. 8.2e-113;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PEDPSDLQHVXKFOSSNFENITWDSGEGTPTVYSEIYKTERPMVAKKGGORITRK 60
DB 1 PEDPSDLQHVXKFOSSNFENITWDSGEGTPTVYSEIYKTERPMVAKKGGORITRK 60
QY 61 SCULTEGNTLLEYAVYAVTSAGRSATKMTFRFSSLOHTTLKPPDVTCISKVRSIQM 120
DB 61 SCULTEGNTLLEYAVYAVTSAGRSATKMTFRFSSLOHTTLKPPDVTCISKVRSIQM 120
QY 121 IVHPTPTPIRAGDGRRLTLEDIFPHDLFYHLELOVNRYYOMHLGGKOREYEFPGITPDT 180
DB 121 IVHPTPTPIRAGDGRRLTLEDIFPHDLFYHLELOVNRYYOMHLGGKOREYEFPGITPDT 180

QY 1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWWAKGCGORITRK 60
 DB 18 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWWAKGCGORITRK 77
 QY 61 SCNLTVETGNLTLYYARVAVSAGRSATKMTDRFSSLOHTTLKPPDVTICISKVRSIQM 120
 DB 78 SCNLTVETGNLTLYYARVAVSAGRSATKMTDRFSSLOHTTLKPPDVTICISKVRSIQM 137
 QY 121 IVHPTPTPIRAGDGHRLTLEDFHDLFYHLELQVNRITYQMHLLGKQREYEFGLTPDTEF 180
 DB 138 IVHPTPTPIRAGDGHRLTLEDFHDLFYHLELQVNRITYQMHLLGKQREYEFGLTPDTEF 197
 QY 181 LGTOMICVPTWAKESAPYMCRCVKTLPDRTWT 211
 DB 198 LGTOMICVPTWAKESAPYMCRCVKTLPDRTWT 228

RESULT 4

US-10-063-547-164
 ; Sequence 164, Application US/10063547
 ; Publication No. US20020182838A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baton, Dan L.
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, Christopher J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Watanabe, Colin K.
 ; APPLICANT: Wood, William I.
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: F3230R1C1
 ; CURRENT APPLICATION NUMBER: US/10/063,547
 ; CURRENT FILING DATE: 2002-05-02
 ; Prior Application removed - See File Wrapper or Palm
 ; NUMBER OF SEQ ID NOS: 170
 ; SEQ ID NO 164
 ; LENGTH: 574
 ; TYPE: PRT
 ; ORGANISM: Homo Sapien
 ; US-10-063-547-164

Query Match 100.0%; Score 1142; DB 9; Length 574;
 Best Local Similarity 100.0%; Pred. No. 3.2e-112;
 Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWWAKGCGORITRK 60
 DB 18 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWWAKGCGORITRK 77
 QY 61 SCNLTVETGNLTLYYARVAVSAGRSATKMTDRFSSLOHTTLKPPDVTICISKVRSIQM 120
 DB 78 SCNLTVETGNLTLYYARVAVSAGRSATKMTDRFSSLOHTTLKPPDVTICISKVRSIQM 137
 QY 121 IVHPTPTPIRAGDGHRLTLEDFHDLFYHLELQVNRITYQMHLLGKQREYEFGLTPDTEF 180
 DB 138 IVHPTPTPIRAGDGHRLTLEDFHDLFYHLELQVNRITYQMHLLGKQREYEFGLTPDTEF 197
 QY 181 LGTOMICVPTWAKESAPYMCRCVKTLPDRTWT 211
 DB 198 LGTOMICVPTWAKESAPYMCRCVKTLPDRTWT 228

RESULT 5

US-09-728-911-25
 ; Sequence 25, Application US/09728911
 ; Patent No. US20020012669A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Presnell, Scott R.
 ; APPLICANT: Xu, Wenfeng
 ; APPLICANT: Kindsvogel, Wayne

QY 181 LGTOMICVPTWAKESAPYMCRCVKTLPDRTWT 211
 DB 181 LGTOMICVPTWAKESAPYMCRCVKTLPDRTWT 211
 RESULT 2
 US-09-912-672A-5
 ; Sequence 5, Application US/09912672A
 ; Patent No. US20020164689A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Busfield, Samantha J.
 ; TITLE OF INVENTION: CLASS II CYTOKINE RECEPTOR-LIKE PROTEINS
 ; TITLE OF INVENTION: AND NUCLEIC ACIDS ENCODING THEM
 ; FILE REFERENCE: 07334-184001
 ; CURRENT APPLICATION NUMBER: US/09/912,672A
 ; CURRENT FILING DATE: 2001-07-23
 ; PRIOR APPLICATION NUMBER: 09/475,541
 ; PRIOR FILING DATE: 1999-12-30
 ; NUMBER OF SEQ ID NOS: 27
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 5
 ; LENGTH: 560
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; US-09-912-672A-5

Query Match 100.0%; Score 1142; DB 9; Length 560;
 Best Local Similarity 100.0%; Pred. No. 3.1e-112;
 Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWWAKGCGORITRK 60
 DB 4 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWWAKGCGORITRK 63
 QY 61 SCNLTVETGNLTLYYARVAVSAGRSATKMTDRFSSLOHTTLKPPDVTICISKVRSIQM 120
 DB 64 SCNLTVETGNLTLYYARVAVSAGRSATKMTDRFSSLOHTTLKPPDVTICISKVRSIQM 123
 QY 121 IVHPTPTPIRAGDGHRLTLEDFHDLFYHLELQVNRITYQMHLLGKQREYEFGLTPDTEF 180
 DB 124 IVHPTPTPIRAGDGHRLTLEDFHDLFYHLELQVNRITYQMHLLGKQREYEFGLTPDTEF 183
 QY 181 LGTOMICVPTWAKESAPYMCRCVKTLPDRTWT 211
 DB 184 LGTOMICVPTWAKESAPYMCRCVKTLPDRTWT 214

RESULT 3
 US-09-912-672A-2
 ; Sequence 2, Application US/09912672A
 ; Patent No. US20020164689A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Busfield, Samantha J.
 ; TITLE OF INVENTION: CLASS II CYTOKINE RECEPTOR-LIKE PROTEINS
 ; TITLE OF INVENTION: AND NUCLEIC ACIDS ENCODING THEM
 ; FILE REFERENCE: 07334-184001
 ; CURRENT APPLICATION NUMBER: US/09/912,672A
 ; CURRENT FILING DATE: 2001-07-23
 ; PRIOR APPLICATION NUMBER: 09/475,541
 ; PRIOR FILING DATE: 1999-12-30
 ; NUMBER OF SEQ ID NOS: 27
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 2
 ; LENGTH: 574
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; US-09-912-672A-2

Query Match 100.0%; Score 1142; DB 9; Length 574;
 Best Local Similarity 100.0%; Pred. No. 3.2e-112;
 Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

; APPLICANT: Chen, Zhi
; TITLE OF INVENTION: Human Cytokine Receptor
; FILE REFERENCE: 99-93
; CURRENT APPLICATION NUMBER: US/09/728,911
; CURRENT FILING DATE: 2000-12-01
; PRIOR APPLICATION NUMBER: US 60/169,049
; PRIOR FILING DATE: 1999-12-03
; PRIOR APPLICATION NUMBER: US 60/232,219
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: US 60/244,610
; PRIOR FILING DATE: 2000-10-31
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 25
; LENGTH: 574
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-728-911-25

```

```

Query Match 100.0%; Score 1142; DB 10; Length 574;
Local Similarity 100.0%; Pred. No. 3.2e-112;
Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 PEDPSDLLQHVKFOSSNFENILTWDSGEGTPTVYSIEKTYGERDPAKKGCGQRTTRK 60
Db 18 PEDPSDLLQHVKFOSSNFENILTWDSGEGTPTVYSIEKTYGERDPAKKGCGQRTTRK 77
Qy 61 SCNLVEGNLTLYAVAVASAGRSATMTDRFSSLOHTTLKPPDVTCISKVRSIQM 120
Db 78 SCNLVEGNLTLYAVAVASAGRSATMTDRFSSLOHTTLKPPDVTCISKVRSIQM 137
Qy 121 IVHPTPTIRAGDGRRLTLEDIFHDLFYHLELVNRYQWHLGGKQREYFPGLTPTDER 180
Db 138 IVHPTPTIRAGDGRRLTLEDIFHDLFYHLELVNRYQWHLGGKQREYFPGLTPTDER 197
Qy 161 LGTIMICVPTWAKESAPYMCVKTLPPDRTWT 211
Db 198 LGTIMICVPTWAKESAPYMCVKTLPPDRTWT 228

```

```

RESULT 6
US-09-870-574-4
; Sequence 4, Application US/09870574
; Patent No. US20020102723A1
; GENERAL INFORMATION:
; APPLICANT: Gurney, Austin L.
; APPLICANT: Aggarwal, Sudeepa
; APPLICANT: Xie, Ming-Hong
; APPLICANT: Maruoka, Ellen M.
; APPLICANT: Foster, Jessica S.
; APPLICANT: Goddard, Audrey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: INTERLEUKIN-22 POLYPEPTIDES, NUCLEIC ACIDS ENCODING
; FILE REFERENCE: P2806-1(US)
; CURRENT APPLICATION NUMBER: US/09/870,574
; CURRENT FILING DATE: 2001-05-30
; PRIOR APPLICATION NUMBER: US 60/169,495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: PCT/US00/14042
; PRIOR FILING DATE: 2000-05-22
; PRIOR APPLICATION NUMBER: PCT/US00/23328
; PRIOR FILING DATE: 2000-08-24
; NUMBER OF SEQ ID NOS: 7
; SEQ ID NO 4
; LENGTH: 574
; TYPE: PRT
; ORGANISM: Homo Sapien
US-09-870-574-4

```

```

Query Match 100.0%; Score 1142; DB 10; Length 574;
Best Local Similarity 100.0%; Pred. No. 3.2e-112;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 PEDPSDLLQHVKFOSSNFENILTWDSGEGTPTVYSIEKTYGERDPAKKGCGQRTTRK 60
Db 18 PEDPSDLLQHVKFOSSNFENILTWDSGEGTPTVYSIEKTYGERDPAKKGCGQRTTRK 77
Qy 61 SCNLVEGNLTLYAVAVASAGRSATMTDRFSSLOHTTLKPPDVTCISKVRSIQM 120
Db 78 SCNLVEGNLTLYAVAVASAGRSATMTDRFSSLOHTTLKPPDVTCISKVRSIQM 137
Qy 121 IVHPTPTIRAGDGRRLTLEDIFHDLFYHLELVNRYQWHLGGKQREYFPGLTPTDER 180
Db 138 IVHPTPTIRAGDGRRLTLEDIFHDLFYHLELVNRYQWHLGGKQREYFPGLTPTDER 197
Qy 161 LGTIMICVPTWAKESAPYMCVKTLPPDRTWT 211
Db 198 LGTIMICVPTWAKESAPYMCVKTLPPDRTWT 228

```

```

RESULT 7
US-10-006-867-164
; Sequence 164, Application US/10006867
; Patent No. US20020119130A1
; GENERAL INFORMATION:
; APPLICANT: Baton, Dan L.
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3230R1C1
; CURRENT APPLICATION NUMBER: US/10/006,867
; CURRENT FILING DATE: 2001-12-06
; PRIOR APPLICATION NUMBER: 60/063435
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/064215
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/082797
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/083495
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088740
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088811
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088825
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088863
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089514
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089653
; PRIOR FILING DATE: 1998-06-17

```


; PRIOR APPLICATION NUMBER: 60/089952
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/090246
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090444
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090688
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090696
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090862
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/091628
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/096012
 ; PRIOR FILING DATE: 1998-08-10
 ; PRIOR APPLICATION NUMBER: 60/096757
 ; PRIOR FILING DATE: 1998-08-17
 ; PRIOR APPLICATION NUMBER: 60/096949
 ; PRIOR FILING DATE: 1998-08-18
 ; PRIOR APPLICATION NUMBER: 60/096959
 ; PRIOR FILING DATE: 1998-08-18
 ; PRIOR APPLICATION NUMBER: 60/097954
 ; PRIOR FILING DATE: 1998-08-26
 ; PRIOR APPLICATION NUMBER: 60/097971
 ; PRIOR FILING DATE: 1998-08-26
 ; PRIOR APPLICATION NUMBER: 60/097979
 ; PRIOR FILING DATE: 1998-08-26
 ; PRIOR APPLICATION NUMBER: 60/098749
 ; PRIOR FILING DATE: 1998-09-01
 ; PRIOR APPLICATION NUMBER: 60/099741
 ; PRIOR FILING DATE: 1998-09-10
 ; PRIOR APPLICATION NUMBER: 60/099763
 ; PRIOR FILING DATE: 1998-09-10
 ; PRIOR APPLICATION NUMBER: 60/099792
 ; PRIOR FILING DATE: 1998-09-10
 ; PRIOR APPLICATION NUMBER: 60/099812
 ; PRIOR FILING DATE: 1998-09-10
 ; PRIOR APPLICATION NUMBER: 60/099815
 ; PRIOR FILING DATE: 1998-09-10
 ; PRIOR APPLICATION NUMBER: 60/100627
 ; PRIOR FILING DATE: 1998-09-16
 ; PRIOR APPLICATION NUMBER: 60/100662
 ; PRIOR FILING DATE: 1998-09-16
 ; PRIOR APPLICATION NUMBER: 60/100683
 ; PRIOR FILING DATE: 1998-09-17
 ; PRIOR APPLICATION NUMBER: 60/100684
 ; PRIOR FILING DATE: 1998-09-17
 ; PRIOR APPLICATION NUMBER: 60/100930
 ; PRIOR FILING DATE: 1998-09-17
 ; PRIOR APPLICATION NUMBER: 60/101279
 ; PRIOR FILING DATE: 1998-09-22
 ; PRIOR APPLICATION NUMBER: 60/101475
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101738
 ; PRIOR FILING DATE: 1998-09-24
 ; PRIOR APPLICATION NUMBER: 60/101743
 ; PRIOR FILING DATE: 1998-09-24
 ; PRIOR APPLICATION NUMBER: 60/101916
 ; PRIOR FILING DATE: 1998-09-24
 ; PRIOR APPLICATION NUMBER: 60/102570
 ; PRIOR FILING DATE: 1998-09-30
 ; PRIOR APPLICATION NUMBER: 60/103449
 ; PRIOR FILING DATE: 1998-10-06
 ; PRIOR APPLICATION NUMBER: 60/103678
 ; PRIOR FILING DATE: 1998-10-08
 ; PRIOR APPLICATION NUMBER: 60/103679
 ; PRIOR FILING DATE: 1998-10-08
 ; PRIOR APPLICATION NUMBER: 60/103711
 ; PRIOR FILING DATE: 1998-10-08
 ; PRIOR APPLICATION NUMBER: 60/105000
 ; PRIOR FILING DATE: 1998-10-20
 ; PRIOR APPLICATION NUMBER: 60/105002

; PRIOR FILING DATE: 1998-10-20
 ; PRIOR APPLICATION NUMBER: 60/105881
 ; PRIOR FILING DATE: 1998-10-27
 ; PRIOR APPLICATION NUMBER: 60/106030
 ; PRIOR FILING DATE: 1998-10-28
 ; PRIOR APPLICATION NUMBER: 60/106464
 ; PRIOR FILING DATE: 1998-10-30
 ; PRIOR APPLICATION NUMBER: 60/106856
 ; PRIOR FILING DATE: 1998-11-03
 ; PRIOR APPLICATION NUMBER: 60/108807
 ; PRIOR FILING DATE: 1998-11-17
 ; PRIOR APPLICATION NUMBER: 60/112419
 ; PRIOR FILING DATE: 1998-12-15
 ; PRIOR APPLICATION NUMBER: 60/112422
 ; PRIOR FILING DATE: 1998-12-15
 ; PRIOR APPLICATION NUMBER: 60/112853
 ; PRIOR FILING DATE: 1998-12-16
 ; PRIOR APPLICATION NUMBER: 60/113011
 ; PRIOR FILING DATE: 1998-12-16
 ; PRIOR APPLICATION NUMBER: 60/112854
 ; PRIOR FILING DATE: 1998-12-16
 ; PRIOR APPLICATION NUMBER: 60/113300
 ; PRIOR FILING DATE: 1998-12-22
 ; PRIOR APPLICATION NUMBER: 60/113408
 ; PRIOR FILING DATE: 1998-12-22
 ; PRIOR APPLICATION NUMBER: 60/113430
 ; PRIOR FILING DATE: 1998-12-23
 ; PRIOR APPLICATION NUMBER: 60/113621
 ; PRIOR FILING DATE: 1998-12-23
 ; PRIOR APPLICATION NUMBER: 60/114223
 ; PRIOR FILING DATE: 1998-12-30
 ; PRIOR APPLICATION NUMBER: 60/115614
 ; PRIOR FILING DATE: 1999-01-12
 ; PRIOR APPLICATION NUMBER: 60/116527
 ; PRIOR FILING DATE: 1999-01-20
 ; PRIOR APPLICATION NUMBER: 60/116843
 ; PRIOR FILING DATE: 1999-01-22
 ; PRIOR APPLICATION NUMBER: 60/119285
 ; PRIOR FILING DATE: 1999-02-09
 ; PRIOR APPLICATION NUMBER: 60/119287
 ; PRIOR FILING DATE: 1999-02-09
 ; PRIOR APPLICATION NUMBER: 60/119525
 ; PRIOR FILING DATE: 1999-02-10
 ; PRIOR APPLICATION NUMBER: 60/119549
 ; PRIOR FILING DATE: 1999-02-10
 ; PRIOR APPLICATION NUMBER: 60/120014
 ; PRIOR FILING DATE: 1999-02-11
 ; PRIOR APPLICATION NUMBER: 60/129122
 ; PRIOR FILING DATE: 1999-04-13
 ; PRIOR APPLICATION NUMBER: 60/129674
 ; PRIOR FILING DATE: 1999-04-16
 ; PRIOR APPLICATION NUMBER: 60/131291
 ; PRIOR FILING DATE: 1999-04-27
 ; PRIOR APPLICATION NUMBER: 60/138387
 ; PRIOR FILING DATE: 1999-06-09
 ; PRIOR APPLICATION NUMBER: 60/144791
 ; PRIOR FILING DATE: 1999-07-20
 ; PRIOR APPLICATION NUMBER: 60/169495
 ; PRIOR FILING DATE: 1999-12-07
 ; PRIOR APPLICATION NUMBER: 60/175481
 ; PRIOR FILING DATE: 2000-01-11
 ; PRIOR APPLICATION NUMBER: 60/191007
 ; PRIOR FILING DATE: 2000-03-21
 ; PRIOR APPLICATION NUMBER: 60/199397
 ; PRIOR FILING DATE: 2000-04-25
 ; PRIOR APPLICATION NUMBER: 09/380139
 ; PRIOR FILING DATE: 1998-08-25
 ; PRIOR APPLICATION NUMBER: 09/311832
 ; PRIOR FILING DATE: 1999-05-14
 ; PRIOR APPLICATION NUMBER: 09/380137
 ; PRIOR FILING DATE: 1999-08-25
 ; PRIOR APPLICATION NUMBER: 09/380138

PRIOR APPLICATION NUMBER: 09/380142

Query Match 100.0%; Score 1142; DB 12; Length 574;
Best Local Similarity 100.0%; Pred. No. 3.2e-112;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PEDPSDLQHVKFQSSNFENILTWDSGPEGTPDYYSIEYKTYGERDWAQKGCORITRK 60
DB 18 PEDPSDLQHVKFQSSNFENILTWDSGPEGTPDYYSIEYKTYGERDWAQKGCORITRK 77
QY 61 SCNLVETGNLTLYARVAVASAGRSATKMTDRFSSLOHTTLKPPDVTCSKVSISOM 120
DB 78 SCNLVETGNLTLYARVAVASAGRSATKMTDRFSSLOHTTLKPPDVTCSKVSISOM 137
QY 121 IVHPTPIRAGDGRHLTLEDIFHDLFYHLELOVNTTYOMHLGKORREVEFFGLTPDTEF 180
DB 138 IVHPTPIRAGDGRHLTLEDIFHDLFYHLELOVNTTYOMHLGKORREVEFFGLTPDTEF 197
QY 181 LGTIMICVPTWAKESAPYMCRCVKTLDPDRTWT 211
DB 198 LGTIMICVPTWAKESAPYMCRCVKTLDPDRTWT 228

RESULT 8
US-09-912-672A-5
Sequence 6, Application US/09912672A
Patent No. US20020164689A1
GENERAL INFORMATION:
APPLICANT: Busfield, Samantha J.
TITLE OF INVENTION: CLASS II CYTOKINE RECEPTOR-LIKE PROTEINS
FILE REFERENCE: 07334-184001
CURRENT APPLICATION NUMBER: US/09/912,672A
PRIOR FILING DATE: 2001-07-23
PRIOR APPLICATION NUMBER: 09/475,541
NUMBER OF SEQ ID NOS: 27
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 6
LENGTH: 212
TYPE: PRT
ORGANISM: Homo sapiens
US-09-912-672A-6

Query Match 98.6%; Score 1126; DB 9; Length 212;
Best Local Similarity 100.0%; Pred. No. 4e-111;
Matches 209; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PEDPSDLQHVKFQSSNFENILTWDSGPEGTPDYYSIEYKTYGERDWAQKGCORITRK 60
DB 4 PEDPSDLQHVKFQSSNFENILTWDSGPEGTPDYYSIEYKTYGERDWAQKGCORITRK 63
QY 61 SCNLVETGNLTLYARVAVASAGRSATKMTDRFSSLOHTTLKPPDVTCSKVSISOM 120
DB 64 SCNLVETGNLTLYARVAVASAGRSATKMTDRFSSLOHTTLKPPDVTCSKVSISOM 123
QY 121 IVHPTPIRAGDGRHLTLEDIFHDLFYHLELOVNTTYOMHLGKORREVEFFGLTPDTEF 180
DB 124 IVHPTPIRAGDGRHLTLEDIFHDLFYHLELOVNTTYOMHLGKORREVEFFGLTPDTEF 183
QY 181 LGTIMICVPTWAKESAPYMCRCVKTLDPDRT 209
DB 184 LGTIMICVPTWAKESAPYMCRCVKTLDPDRT 212

RESULT 9
US-09-912-672A-20
Sequence 20, Application US/09912672A
Patent No. US20020164689A1
GENERAL INFORMATION:
APPLICANT: Busfield, Samantha J.
TITLE OF INVENTION: CLASS II CYTOKINE RECEPTOR-LIKE PROTEINS
TITLE OF INVENTION: AND NUCLEIC ACIDS ENCODING THEM

FILE REFERENCE: 07334-184001
CURRENT APPLICATION NUMBER: US/09/912,672A
CURRENT FILING DATE: 2001-07-23
PRIOR APPLICATION NUMBER: 09/475,541
PRIOR FILING DATE: 1999-12-30
NUMBER OF SEQ ID NOS: 27
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 20
LENGTH: 353
TYPE: PRT
ORGANISM: Mus musculus
US-09-912-672A-20

Query Match 60.5%; Score 691; DB 9; Length 353;
Best Local Similarity 78.5%; Pred. No. 5e-65;
Matches 128; Conservative 13; Mismatches 22; Indels 0; Gaps 0;

QY 48 WYAKGCGRITRKSCNLTVEGNTLYARVAVASAGRSATKMTDRFSSLOHTTLKPP 107
DB 1 WYAKGCGRITRKSCNLTVEGNTLYARVAVASAGRSATKMTDRFSSLOHTTLKPP 60
QY 108 DVTCSKVSISOMIVHPTPIRAGDGRHLTLEDIFHDLFYHLELOVNTTYOMHLGKOR 167
DB 61 DVTCSKVSISOMIVHPTPIRAGDGRHLTLEDIFHDLFYHLELOVNTTYOMHLGKOR 120
QY 168 EYEFGLTPDTEFLGTIMICVPTWAKESAPYMCRCVKTLDPDRTWT 210
DB 121 EYEFGLTPDTEFLGTIMICVPTWAKESAPYMCRCVKTLDPDRTWT 163

RESULT 10
US-09-912-672A-9
Sequence 9, Application US/09912672A
Patent No. US20020164689A1
GENERAL INFORMATION:
APPLICANT: Busfield, Samantha J.
TITLE OF INVENTION: CLASS II CYTOKINE RECEPTOR-LIKE PROTEINS
FILE REFERENCE: 07334-184001
CURRENT APPLICATION NUMBER: US/09/912,672A
PRIOR FILING DATE: 2001-07-23
PRIOR APPLICATION NUMBER: 09/475,541
NUMBER OF SEQ ID NOS: 27
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 9
LENGTH: 68
TYPE: PRT
ORGANISM: Homo sapiens
US-09-912-672A-9

Query Match 32.0%; Score 365; DB 9; Length 68;
Best Local Similarity 100.0%; Pred. No. 1.1e-31;
Matches 68; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 21 ILTWDSGPEGTPDYYSIEYKTYGERDWAQKGCORITRKSCNLVETGNLTLYARV 80
DB 1 ILTWDSGPEGTPDYYSIEYKTYGERDWAQKGCORITRKSCNLVETGNLTLYARV 60
QY 81 AVSAGRS 88
DB 61 AVSAGRS 68

RESULT 11
US-09-728-911-13
Sequence 13, Application US/09728911
Patent No. US20020012668A1
GENERAL INFORMATION:
APPLICANT: Presnell, Scott R.
APPLICANT: Xu, Wenfeng
APPLICANT: Kinsvogel, Wayne
APPLICANT: Chen, Zhi

;; TITLE OF INVENTION: Human Cytokine Receptor
;; FILE REFERENCE: 99-93
;; CURRENT APPLICATION NUMBER: US/09/728,911
;; CURRENT FILING DATE: 2000-12-01
;; PRIOR APPLICATION NUMBER: US 60/169,049
;; PRIOR FILING DATE: 1999-12-03
;; PRIOR APPLICATION NUMBER: US 60/232,219
;; PRIOR FILING DATE: 2000-09-13
;; PRIOR APPLICATION NUMBER: US 60/244,610
;; PRIOR FILING DATE: 2000-10-31
;; NUMBER OF SEQ ID NOS: 36
;; SOFTWARE: FastSeq for Windows Version 3.0
;; SEQ ID NO 13
;; LENGTH: 210
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-09-728-911-13

Query Match 23.0%; Score 263; DB 10; Length 210;
Best Local Similarity 34.0%; Pred. No. 2.7e-20;
Matches 66; Conservative 29; Mismatches 87; Indels 12; Gaps 4;

QY 9 QHVKFQSNFENILTWDSGPEGTDP-TVYSIEYKTYGERDWAKGQCORITRKSCNLTVE 67
DB 11 QRVQFQSRNFHILQWQGRALTGNSVYFVQYKIYQORQWKNKEDCWGTQELSCDLTSE 70
QY 68 TGNLTLEYARVTAVSAGRSATKMTDRFSSLOHTTLKPPDVTCISKVRSIQMIVHPTPT 127
DB 71 TSDIQEPYGRVRAASAGSYSEWSMTPTPTWETKIDPPVNMITQVNGSLLVILHAPNL 130
QY 128 PIRAGDGHRLTLEDFHDLFYHLEQVN-----RTYQMHLLGGKQREYFFGLTPDTEFL 181
DB 131 PIRYQKEKNVSIED-YVELLYRVFIINNSLEKEQKVE----GAHRAVEIEALTPHSSYC 185
QY 182 GTIMICVPTWAKES 195
DB 186 VVAEIYQPMLEDRRS 199

RESULT 12
US-09-728-911-2
; Sequence 2, Application US/09728911
; Patent No. US20020012669A1
; GENERAL INFORMATION:
; APPLICANT: Presnell, Scott R.
; APPLICANT: Xu, Wenfeng
; APPLICANT: Kindsvogel, Wayne
; APPLICANT: Chen, Zhi
; TITLE OF INVENTION: Human Cytokine Receptor
; FILE REFERENCE: 99-93
; CURRENT APPLICATION NUMBER: US/09/728,911
; CURRENT FILING DATE: 2000-12-01
; PRIOR APPLICATION NUMBER: US 60/169,049
; PRIOR FILING DATE: 1999-12-03
; PRIOR APPLICATION NUMBER: US 60/232,219
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: US 60/244,610
; PRIOR FILING DATE: 2000-10-31
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 231
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-728-911-2

Query Match 23.0%; Score 263; DB 10; Length 231;
Best Local Similarity 34.0%; Pred. No. 3.1e-20;
Matches 66; Conservative 29; Mismatches 87; Indels 12; Gaps 4;

QY 9 QHVKFQSNFENILTWDSGPEGTDP-TVYSIEYKTYGERDWAKGQCORITRKSCNLTVE 67
DB 32 QRVQFQSRNFHILQWQGRALTGNSVYFVQYKIYQORQWKNKEDCWGTQELSCDLTSE 91

QY 68 TGNLTLEYARVTAVSAGRSATKMTDRFSSLOHTTLKPPDVTCISKVRSIQMIVHPTPT 127
DB 92 TSDIQEPYGRVRAASAGSYSEWSMTPTPTWETKIDPPVNMITQVNGSLLVILHAPNL 151
QY 128 PIRAGDGHRLTLEDFHDLFYHLEQVN-----RTYQMHLLGGKQREYFFGLTPDTEFL 181
DB 152 PIRYQKEKNVSIED-YVELLYRVFIINNSLEKEQKVE----GAHRAVEIEALTPHSSYC 206
QY 182 GTIMICVPTWAKES 195
DB 207 VVAEIYQPMLEDRRS 220

RESULT 13
US-09-949-192-6
; Sequence 6, Application US/09949192
; Patent No. US20020142292A1
; GENERAL INFORMATION:
; APPLICANT: Parham, Christi L.
; APPLICANT: Gorman, Daniel L.
; APPLICANT: Kurata, Hirokazu
; APPLICANT: Arai, Naoko
; APPLICANT: Sana, Theodore R.
; APPLICANT: Mattson, Jeanine D.
; APPLICANT: Murphy, Erin E.
; APPLICANT: Savkoor, Chetan
; APPLICANT: Grein, Jeffery
; APPLICANT: Smith, Kathleen M.
; APPLICANT: McCLanahan, Terrill K.
; TITLE OF INVENTION: MAMMALIAN GENES; RELATED REAGENTS AND METHODS
; FILE REFERENCE: DX01169K
; CURRENT APPLICATION NUMBER: US/09/949,192
; CURRENT FILING DATE: 2001-09-07
; PRIOR APPLICATION NUMBER: 60/231,267
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 231
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-949-192-6

Query Match 23.0%; Score 263; DB 10; Length 231;
Best Local Similarity 34.0%; Pred. No. 3.1e-20;
Matches 66; Conservative 29; Mismatches 87; Indels 12; Gaps 4;

QY 9 QHVKFQSNFENILTWDSGPEGTDP-TVYSIEYKTYGERDWAKGQCORITRKSCNLTVE 67
DB 32 QRVQFQSRNFHILQWQGRALTGNSVYFVQYKIYQORQWKNKEDCWGTQELSCDLTSE 91
QY 68 TGNLTLEYARVTAVSAGRSATKMTDRFSSLOHTTLKPPDVTCISKVRSIQMIVHPTPT 127
DB 92 TSDIQEPYGRVRAASAGSYSEWSMTPTPTWETKIDPPVNMITQVNGSLLVILHAPNL 151
QY 128 PIRAGDGHRLTLEDFHDLFYHLEQVN-----RTYQMHLLGGKQREYFFGLTPDTEFL 181
DB 152 PIRYQKEKNVSIED-YVELLYRVFIINNSLEKEQKVE----GAHRAVEIEALTPHSSYC 206
QY 182 GTIMICVPTWAKES 195
DB 207 VVAEIYQPMLEDRRS 220

RESULT 14
US-09-746-359A-55
; Sequence 55, Application US/09746359A
; Patent No. US20020042366A1
; GENERAL INFORMATION:
; APPLICANT: Thompson, Penny
; APPLICANT: Foster, Donald C.
; APPLICANT: Xu, Wenfeng

```
APPLICANT: Madden, Karen L.
APPLICANT: Kelly, James D.
APPLICANT: Sprecher, Cindy A.
APPLICANT: Blumberg, Hal
APPLICANT: Eagan, Maribeth A.
APPLICANT: Jasper, Stephen R.
APPLICANT: Chandrasekher, Yashmin A.
APPLICANT: No. US20020042366A1ak, Julia E.
TITLE OF INVENTION: Method for Treating Inflammation
FILE REFERENCE: 99-108
CURRENT APPLICATION NUMBER: US/09/746,359A
PRIOR FILING DATE: 2001-05-21
PRIOR APPLICATION NUMBER: 60/171,969
PRIOR FILING DATE: 1999-12-23
PRIOR APPLICATION NUMBER: 60/213,341
NUMBER OF SEQ ID NOS: 72
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 55
LENGTH: 217
TYPE: PRT
ORGANISM: Homo sapiens
US-09-746-359A-55
```

```
Query Match 16.8%; Score 191.5; DB 10; Length 217;
Best Local Similarity 25.6%; Pred. No. 9.6e-13;
Matches 55; Conservative 44; Mismatches 89; Indels 27; Gaps 8;

Qy 10 HVKFOSSNPNENILTWDSGPEGTP--DTVYSIEYKTGGERDVAKKGCORITRKSCLTVE 67
Db 13 NITFLSINKKVLQW-TPEGLQGVKVTYQYFIYQKKMLNKBECRNINRTYCDLSAE 71
Qy 68 TGNLTLYARVAVSAGRSATKMTDRFSSLOHTTLKPPDVTCSIKVRSIQMIV----- 122
Db 72 TSDYEHQYAKKAIWGTCKSKMAESGRFYPFLETOIGPEVALTTDEKSIIVLTAPK 131
Qy 123 ---HPTPPPIRAGDGRHLTLEDIFHDLFYH---LELOVNRITYQMHLGKOREYEFGLTP 176
Db 132 WKRNPEDDLVP-----SMOOIYSNLKYNVSVLNTKSNRTWSQCV--TNHTLVLTWLEP 181
Qy 177 DTEPLGTIMICVPTWAKESAP--YMCRAVKTLPDRT 209
Db 182 NTLVCVHVESFVPGPPRAQPSSEKQC-ARTLKDQS 215
```

```
RESULT 15
US-09-746-359A-12
Sequence 12, Application US/09746359A
Patent No. US20020042366A1
GENERAL INFORMATION:
APPLICANT: Thompson, Penny
APPLICANT: Foster, Donald C.
APPLICANT: Xu, Wenfeng
APPLICANT: Madden, Karen L.
APPLICANT: Kelly, James D.
APPLICANT: Sprecher, Cindy A.
APPLICANT: Blumberg, Hal
APPLICANT: Eagan, Maribeth A.
APPLICANT: Jasper, Stephen R.
APPLICANT: Chandrasekher, Yashmin A.
APPLICANT: No. US20020042366A1ak, Julia E.
TITLE OF INVENTION: Method for Treating Inflammation
FILE REFERENCE: 99-108
CURRENT APPLICATION NUMBER: US/09/746,359A
PRIOR FILING DATE: 2001-05-21
PRIOR APPLICATION NUMBER: 60/171,969
PRIOR FILING DATE: 1999-12-23
PRIOR APPLICATION NUMBER: 60/213,341
NUMBER OF SEQ ID NOS: 72
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 12
LENGTH: 221
```

```
TYPE: PRT
ORGANISM: Homo sapiens
US-09-746-359A-12
Query Match 16.8%; Score 191.5; DB 10; Length 221;
Best Local Similarity 25.6%; Pred. No. 9.9e-13;
Matches 55; Conservative 44; Mismatches 89; Indels 27; Gaps 8;

Qy 10 HVKFOSSNPNENILTWDSGPEGTP--DTVYSIEYKTGGERDVAKKGCORITRKSCLTVE 67
Db 13 NITFLSINKKVLQW-TPEGLQGVKVTYQYFIYQKKMLNKBECRNINRTYCDLSAE 71
Qy 68 TGNLTLYARVAVSAGRSATKMTDRFSSLOHTTLKPPDVTCSIKVRSIQMIV----- 122
Db 72 TSDYEHQYAKKAIWGTCKSKMAESGRFYPFLETOIGPEVALTTDEKSIIVLTAPK 131
Qy 123 ---HPTPPPIRAGDGRHLTLEDIFHDLFYH---LELOVNRITYQMHLGKOREYEFGLTP 176
Db 132 WKRNPEDDLVP-----SMOOIYSNLKYNVSVLNTKSNRTWSQCV--TNHTLVLTWLEP 181
Qy 177 DTEPLGTIMICVPTWAKESAP--YMCRAVKTLPDRT 209
Db 182 NTLVCVHVESFVPGPPRAQPSSEKQC-ARTLKDQS 215
```

Search completed: January 13, 2003, 15:44:36
Job time : 7.68662 secs

